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Background: GAVI’s focus on reducing inequities in access to vaccines, immunization, and GAVI funds, − both
between and within countries - has changed over time. This paper charts that evolution.
Methods: A systematic qualitative review was conducted by searching PubMed, Google Scholar and direct review
of available GAVI Board papers, policies, and program guidelines. Documents were included if they described or
evaluated GAVI policies, strategies, or programs and discussed equity of access to vaccines, utilization of immunization
services, or GAVI funds in countries currently or previously eligible for GAVI support. Findings were grouped thematically,
categorized into time periods covering GAVI’s phases of operations, and assessed depending on whether the approaches
mediated equity of opportunity or equity of outcomes between or within countries.
Results: Serches yielded 2816 documents for assessment. After pre-screening and removal of duplicates, 552 documents
underwent detailed evaluation and pertinent information was extracted from 188 unique documents. As a
global funding mechanism, GAVI responded rationally to a semi-fixed funding constraint by focusing on
between-country equity in allocation of resources. GAVI’s predominant focus and documented successes have
been in addressing between-country inequities in access to vaccines comparing lower income (GAVI-eligible)
countries with higher income (ineligible) countries. GAVI has had mixed results at addressing between-country
inequities in utilization of immunization services, and has only more recently put greater emphasis and resources
towards addressing within-country inequities in utilization to immunization services. Over time, GAVI has progressively
added vaccines to its portfolio. This expansion should have addressed inter-country, inter-regional, inter-generational
and gender inequities in disease burden, however, evidence is scant with respect to final outcomes.
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Conclusion: In its next phase of operations, the Alliance can continue to demonstrate its strength as a highly effective
multi-partner enterprise, capable of learning and innovating in a world that has changed much since its inception. By
building on its successes, developing more coherent and consistent approaches to address inequities between and
within countries and by monitoring progress and outcomes, GAVI is well-positioned to bring the benefits of vaccination
to previously unreached and underserved communities towards provision of universal health coverage.
Keywords: Global alliance for vaccines and immunization, GAVI alliance, Gavi—the vaccine alliance, Equity of access to
vaccines, Equity of access to immunization, Immunization coverage disparities, Gender inequality in immunization,
Immunization resource allocation mechanisms, GAVI budget caps, GAVI eligibility, GAVI policies.
Background
Gavi, the Vaccine Alliance (formerly known as the ‘GAVI
Alliance’, and prior to that the ‘Global Alliance for
Vaccines and Immunization’ and hereafter referred to as
‘GAVI’, ‘the Alliance’ or ‘the GAVI Alliance’) was launched
in the year 2000. After fifteen years of operations, GAVI
has developed a strategic framework to articulate priorities
and program investments for its next five-years of opera-
tions (2016 through 2020). The GAVI Board - which
governs activities funded by the Alliance - requested that
in its next phase of operations, GAVI deepen its focus on
improving the coverage and equitable distribution of
immunization services in GAVI countries1 [1–3].
GAVI’s new 2016–2020 strategy and operational plans
will ultimately be framed within the broader context of
the Post-2015 sustainable development agenda. Recent
consultations on the Post-2015 agenda for health sug-
gest the need for equity in access and utilization of
healthcare between and within countries. As such,
people (rather than states or institutions) will be at
the heart of the sustainable development agenda [4–9].
This builds on the growing recognition that existing
global development goals - with their focus on national
averages - have resulted in unequally distributed gains,
and at worst have inadvertently exacerbated inequities
in access within countries, particularly for child health
[10–14]. By contrast, a growing body of evidence sug-
gests that addressing these inequities could drastically
reduce child mortality in low and middle income
countries [15, 16].
GAVI’s approach in 2016 and beyond will need to
draw upon the Alliance’s previous successes as well as
areas identified for improvement. Many of these areas
have been documented in a cadre of retrospective evalua-
tions since GAVI’s formation and over its previous two
phases of operations [Formation and Phase I (1999–2005),
and Phase II (2006–2010)] [17–26]. GAVI’s operations
in its next strategic period will also draw upon more
recent results which are being gleaned in ongoing
retrospective [27]2 and prospective evaluations [28]
for the current phase of GAVI’s operations, Phase III
(2011–2015).
Despite a wealth of information, GAVI’s efforts to ad-
dress inequities in immunization —through its strategies,
policies and resource allocation mechanics—have not
been explicitly mapped out.3 This paper delineates
how GAVI’s focus on equity has evolved and seeks to
identify the range of opportunities that may further




A systematic qualitative review of the literature4 was
undertaken to assess how GAVI’s approach to address
equity/inequity5 in immunization has evolved over time.
Since equity is itself a comparative concept, this paper
focuses on various comparisons between countries, and
within countries.
 Between-country equity is concerned with differences
between countries, either comparing GAVI-eligible
and ineligible countries, or comparing GAVI-eligible
countries to one another;
 Within-country equity is concerned with differences
amongst populations residing within the national
borders of a GAVI-eligible country, where populations
may be stratified either by geography, socioeconomic
status, or gender.
This paper separates out the ‘differences’ in which
GAVI’s strategic, policy and programmatic choices have
addressed or have been driven by concerns related to
equity of opportunity as opposed to equity of outcomes
[29, 30]. This paper considers equity of opportunity in two
interlinked ways:
(i) Opportunity to access specific antigens/ vaccines
(ii) Opportunity to access (or be allocated) GAVI
resources
This paper considers equity of outcomes in terms of
the following intermediate and final outcomes:
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(iii).Intermediate outcomes in terms of coverage or
utilization of immunization services
(iv).Final outcomes in terms of impact on vaccine
preventable disease (VPDs)
Not all combinations of between/within country
equity, equity of opportunity/outcomes are considered
to be relevant for this analysis . For example, since GAVI
has provided support to national rather than subnational
governments, it is only relevant to assess GAVI’s impact
on the equity of opportunity to access GAVI resources
between countries (rather than within countries). By ex-
tension, since GAVI helps facilitate vaccine introductions
into National Immunization Programs (NIPs), and since
NIPs mostly aim to deliver a single schedule of vaccines
across the country,6 it is most relevant to assess GAVI’s
contribution to equity of opportunity to access specific an-
tigens/ vaccines between countries (rather than within
countries).
Finally, when assessing strategies, policies or programs
that concern the distribution of- GAVI resources, this
paper makes distinctions between whether GAVI’s dis-
tributive approaches have been driven by attempts to en-
sure horizontal equity (i.e. ‘equal treatment for equivalent
needs’) or vertical equity (‘preferential treatment for those
with greater health needs’) [31, 32].
Literature review strategy
Table 1 summarizes the literature review strategy.
Conventional steps of a literature review were followed,
i.e. searching the literature, extracting relevant informa-
tion, and assessing the quality of included papers. Two
open-source electronic databases (National Library of
Medicine’s PubMed, Google Scholar) were included in the
search. Given the importance of specific grey literature to
this review, one website (the GAVI Alliance website) and a
private electronic archive (belonging to United Nations
Children’s Fund (UNICEF)) were searched. The electronic
archive was searched because from 1999 until 2008,
UNICEF housed the GAVI Secretariat and hence held a
small electronic repository of GAVI documents; further-
more the GAVI Secretariat published its Board papers
only from the moment it gained independence from
UNICEF; i.e. from 2009 onwards.
Grey literature focused on papers written/published by
the GAVI Secretariat (i.e. GAVI Board papers, GAVI
Committee7 papers, GAVI policies/strategies/program
documents) or independent evaluations of GAVI policies/
programs. Hereafter, these sources are referred to as
‘GAVI documents’.
The pool of evidence was restricted by year of publica-
tion in order to identify papers dealing with the period
immediately before GAVI’s inception to ascertain the
motivations for the formation of GAVI, as well as the
subsequent period that the GAVI Alliance has func-
tioned. Inclusion criteria and search terms were selected
in order to focus the review to the scope and objectives
outlined above.
Information was extracted from all identified documents
meeting inclusion criteria and based on an assessment of
relevance to the study objectives and scope. Extracted
information from all papers included in the review were
categorized thematically according to eleven strategy,
policy, and programmatic pillars that have defined GAVI
since inception:
1. Overarching strategy and workplans
2. Vaccine priorities and New Vaccine Support (NVS)
3. Supply and procurement strategies
4. Country eligibility policies and program filters
5. Large countries and budget cap policies
6. Cash-based support for program/system
strengthening and guidelines
7. Vaccine introduction grants (VIGs), policies and
guidelines
8. Financial sustainability (co-financing) policies
9. ‘Fragile States’ policies
10. Gender policy
11. Vaccine and cash-based program funding prioritization
GAVI itself, its policies, and its strategies have changed
over time. The assessment therefore applies a temporal
lens to further collate the information. Each of the
above-mentioned thematic categorizations have been
sub-divided according to three time periods associated
with GAVI’s operational ‘phases’:
I. Formation/Phase I (1999–2005)—The formative
years and GAVI’s first phase of operations
II. Phase II (2006–2010)—The second phase of GAVI
Alliance operations
III. Phase III (2011–2015)—The third and current
phase of GAVI Alliance operations
Finally, despite the non-clinical nature of the subject
matter, the PRISMA guidelines [33] were followed as
appropriate to conduct the literature review. The
PRISMA Checklist has been completed and is provided in
Additional file 1.
Handling of bias and validity
The methods for this review of qualitative evidence draw
upon guidance delineated by Booth (2001) and Shaw et al.
(2004) concerning the conduct of systematic review and
literature search of qualitative evidence [34, 35]. Accord-
ingly, methods employed for source identification have
been designed to a) identify major “schools of thought”; b)
bring different views through multi- disciplinary searches;
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c) draw upon complementary electronic and manual
search techniques to ensure that materials are not missed.
Rather than rejecting sources a priori based on the study
design or where the information was published, instead
additional weight has been assigned to the findings or
narrative explanations from more robust and/or unbiased
evidence in summarizing the evidence overall. These
approaches lend themselves to greater heterogeneity of
inputs which was deemed permissible in the context of
this review since much of the material reviewed is neither
primary nor secondary research (but rather policies,
program guidelines, meeting minutes etc.). This review
was approached with cognizance of the criteria to critic-
ally appraise findings from qualitative research [36]. Issues
of error, bias and validity as well as trustworthiness of the
sources themselves were carefully considered [37, 38].
Given the significant use of grey literature, there are a
number of ways in which bias, validity and trustworthiness
have been handled. Regarding validity and trustworthi-
ness, the focus of grey literature searches has been on
‘GAVI documents’ (GAVI Board and Committee Papers
and Minutes, formally commissioned rigorous independ-
ent evaluations, GAVI program guidelines, GAVI progress
reports etc.). In general, GAVI Board/Committee Papers
and GAVI Board/Committee Minutes are reviewed and
scrutinized by many stakeholder organizations and con-
stituencies that make up the Alliance including normative
agencies such the WHO, multilateral agencies such as the
World Bank, and experts from sovereign governments
(both within Ministries of Health within GAVI countries,
and Ministries of Foreign Affairs/Ministries of Develop-
ment Cooperation in donor governments). GAVI Board
Minutes are also subject to a formalized sign-off process
to ensure that all parties are satisfied that the Minutes are
a true reflection of proceedings. As such, GAVI docu-
ments - and particularly the Minutes and Board-approved
policies and programs cited - largely reflect the consensus
of the Alliance, rather than the biased position of any sin-
gle actor. Most importantly, to minimize some reporting
biases (e.g. associated with the groupthink of the Alliance),
aside from the peer-reviewed citations, maximum weight
was given to the independent evaluations of GAVI
programs and policies.
Some reporting biases could not be controlled such as
publication bias (e.g. associated with the publication and
reporting of positive results). To address these deficien-
cies, absence of specific and relevant evidence is
highlighted (e.g. where GAVI work plans note a particu-
lar intervention to address inequities, but no results have
been reported/published).
Results
PubMed and Google Scholar searches yielded 120 and
2094 results respectively, while 602 GAVI Board papers
Table 1 Literature review strategy
Electronic database PubMed, Google Scholar
Websites searched GAVI Alliance website
Electronic archives UNICEF
Additional sources Supporting references of all papers meeting criteria (below) yielded from searching the sources (above)
were also reviewed.
Inclusion criteria • Dealt explicitly with the GAVI Alliance (e.g. described findings from GAVI evaluations; detailed GAVI programs,
policies, and/or resource allocation decisions)
• Explicitly discussed inequities/inequalities in access to vaccines, inequities/inequalities in coverage of
immunization services, or inequities/inequalities in access/allocation to GAVI funds
• Related to one or more country which is, or has been, eligible to receive GAVI support since GAVI’s inception
Search updated to 01 November 2014
Restriction on language English only
Restriction on year of publication Published between 1998 and 2014 inclusive
Search terms Terms used for PubMed searches were “Global Alliance for Vaccines and Immunizations” OR “GAVI Alliance” OR
“(GAVI)” AND “equity” OR “inequity” OR “equitable” OR “inequitable” OR “disparity”, OR “inequality”, OR “access to
funds”, OR “access to vaccines”, OR “resource allocation”, OR “coverage deficits”, OR “immunization coverage”.
For Google Scholar, many of the same search terms were used; notably “GAVI Alliance” AND “equity” OR
“equality” OR “access” OR “coverage” OR “resource allocation”
In reviewing unpublished grey literature and GAVI documents, key word searches were performed using
the same terms as used for Google Scholar searches.
Categorization of papers identified Papers meeting the inclusion criteria were categorized according to three time periods (Phase I: 1999–2005;
Phase II: 2006–2010; Phase III: 2011–2015) and according to GAVI’s main policies, strategies, programs (strategy
and work plan, vaccine priorities and new vaccine support, country eligibility policy, large countries and budget
caps policies, program filters, cash-based support for program/system strengthening, vaccine introduction grants,
financial sustainability policy, supply and procurement strategy, fragile states policy, program funding
prioritization, gender policy)
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were collated from online and electronic archives.
Following a review of titles and abstracts, 2227 papers
were excluded due to lack of relevance. After removal of
duplicates, a total of 544 unique documents underwent
detailed evaluation. Based on these reviews 424 papers
were excluded because they were found not to meet the
inclusion/exclusion criteria, but a further 60 papers were
identified (e.g. from reference lists). Pertinent informa-
tion was extracted from the remaining 188 unique docu-
ments. Fig. 1 illustrates the article selection process
while Fig. 2 details the composition of documents
included in the final results. (See Additional file 2 for
further details.)
Table 2 summarizes the main results from the qualita-
tive systematic review. It illustrates each of the eleven
strategy/policy/program pillars across the three phases
of GAVI operations for equity of outcomes and equity of
opportunity (final/intermediate). The table categorizes
the findings according to:
 Whether a conceptual approach was articulated to
address between- or within- country inequities
 The strength/breadth of the evidence to illustrate
the effect/impact of the GAVI strategy, policy, or
program in question
 Whether this evidence suggests positive and/or
negative impacts on the particular inequities
 Whether it is not relevant to assess (because there is
no way that a strategy, policy, or program here











Total papers (peer-reviewed and grey literature)
identified for retrieval 
n=2816
Additional papers (peer-reviewed and grey
literature)identified from other sources
(e.g. reference lists of retrieved papers)
n=60
Papers excluded for valid reason
following detailed evaluation
(e.g. not meeting inclusion criteria) 
n=424
Peer-reviewed and grey




Papers screened and 
subsequently 
removed on grounds 
of relevance
n=2227
Fig. 1 Schematic of article selection
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 Whether it is not applicable (because there was no
specific strategy, policy, or program articulated for
particular phase of operations)
Overarching strategy and workplans
Formation/Phase I
Evidence from the formative years of GAVI, and its pre-
cursor, the Children’s Vaccine Initiative (CVI), suggests
that one of the key motivating factors for setting up a
partnership to focus on vaccines and immunizations was
to address the disparities in access to so-called ‘new and
under-utilized vaccines’ between high income and lower
income countries, as observed by GAVI’s founders [39–
41]. GAVI’s founders included philanthropic institutions
(Bill & Melinda Gates Foundation and the Rockefeller
Foundation), a small number of sovereign donors (the
UK, USA, Norway, Netherlands, Denmark, and Sweden)
and partner multilateral agencies (UNICEF, WHO and
the World Bank) [17, 40].Individuals from these institu-
tions coalesced around the notion that the central prob-
lems facing these countries were inadequate global
supply capacity of new vaccines and insufficient domes-
tic financing (to create a viable market for, and fund the
purchases of newer more expensive vaccines) which man-
ifested in unaffordable prices. In this regard, the Alliance
was primarily set up to address between-country inequi-
ties, between the poorest and wealthier countries, and to
increase the number of people worldwide benefiting from
vaccination [42–44].8
At the time of GAVI's formation there were disparities
between countries in rates of national immunization
coverage with apparent divisions between strong, well-
managed and well-financed programs, and weaker
programs with more uncertain financing (with the latter
group characterized by stagnating or declining coverage,
and/or an inability to sustain gains achieved in the
1980’s through earlier concerted global immunization ef-
forts) [45–47]. However, the discourse from that time
does not suggest a strong and unanimously articulated
motivation to address within-country inequities in access
to immunization services. Despite relatively less emphasis
on within-country disparities in documents pertaining to
GAVI’s formation discussions, their importance was impli-
citly considered. At GAVI’s proto-board meeting in July
1999, a mission statement was adopted that underscored
the importance of both achieving final outcomes to reduce
VPD burden and facilitate each child’s rights to a life free
from these diseases (“To fulfill the right of every child to be
protected against vaccine preventable diseases of public
health concern”). A rights-based approach implies univer-
sality and a desire to remediate inequities in the burden of
VPDs faced by all individuals irrespective of socioeco-
nomic, geographic circumstance or gender. To that extent
it could be argued that within-country equity concerns
were enshrined in GAVI’s stated aims from the outset – at
least at the mission statement level. At the same proto-
board meeting five milestones were established to monitor
the effectiveness of the new immunization partnership,
one of which addressed equity and specifically reductions
in within-country geographic inequities (“By 2005, 80 % of
developing countries should have routine immunization
coverage of at least 80 % in all districts (e.g. as measured
by DTP3 and measles)”) [48].
At GAVI’s second Board meeting which coincided with
the official launch event of the Alliance (during the
World Economic Forum in Davos, Switzerland), the
Fig. 2 Types of sources of information (N = 188)
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Table 2 Summary of main findings
Key GAVI strategy, policy
and programme pillar
EQUITY OF OPPORTUNITY EQUITY OF OUTCOME (Intermediate) EQUITY OF OUTCOME (Final)
Between-country equity comparing Between-country equity comparing Within-country equity comparing Between-country equity comparing
(i) access to new/
underutilized vaccines:

































1. Overarching strategy and workplans
Phase I ++ -(+) ++ -(+) +(+) +(+) ++ -(+) ++ + +
Phase II ++ -(+) ++ -(+) +(+) +(+) ++ -(+) – -(+) -(+)
Phase III + -(+) + -(+) + + + + + – –
2. Vaccine Priorities, NVS and guidelines
Phase I ++ -(+) ++ -(+) N/R N/R + – + ++ -(+)
Phase II ++ ++ ++ ++ N/R N/R – – – ++ ++
Phase III + + + + N/R N/R + + + + +
3. Supply and procurement strategies
Phase I +(+) N/R +(+) N/R N/R N/R N/R N/R N/R N/R N/R
Phase II +(+) N/R +(+) N/R N/R N/R N/R N/R N/R N/R N/R
Phase III + N/R + N/R N/R N/R N/R N/R N/R N/R N/R
4. Country eligibility and program filters
Phase I + +(+) + +(+) +(+) +(+) – – – – –
Phase II +(+) +(+) +(+) +(+) +(+) +(+) – – – – –
Phase III +(+) +(+) +(+) +(+) +(+) +(+) – – – – –
5. Large countries and budget cap policies
Phase I N/R N/R N/R N/R – – -(+) – – – –
Phase II N/R N/R N/R N/R – – -(+) – – – –
Phase III N/R + N/A N/R + N/A N/R + N/A N/R + N/A N/R + N/A N/A N/A N/A N/A N/A N/A
6. Cash-based support and guidelines
Phase I N/R N/A N/R N/A – – -(+) – – – –
Phase II N/R N/A N/R N/A – – +(+) +(+) – – –
Phase III N/R N/A N/R N/A – – + + + – –
7. Vaccine introduction grants (VIGs) policies
Phase I N/R N/A N/R N/A – – – – – – –
Phase II N/R N/A N/R N/A – – – – – – –












Table 2 Summary of main findings (Continued)
8. Financial sustainability (Co-financing)
Phase I N/R – N/R – N/R N/R – – – – –
Phase II N/R + N/R + N/R N/R – – – – –
Phase III N/R + N/R + N/R N/R – – – – –
9. ‘Fragile States’ policies
Phase I – -(+) – -(+) – – – – – – –
Phase II – – – – – – + – – – –
Phase III + + + + + + + + + + –
10. Gender Policy
Phase I N/R + N/A N/A N/R + N/A N/A N/R + N/A N/A N/A N/A N/A N/R + N/A N/A
Phase II N/R N/R N/R N/R – – N/R N/R + – –
Phase III N/R N/R N/R N/R – – N/R N/R + – –
11. Programme prioritization
Phase I N/R + N/A N/A N/R + N/A N/A N/R + N/A N/A N/A N/A N/A N/R + N/A N/A
Phase II N/R + N/A N/A N/R + N/A N/A N/R + N/A N/A N/A N/A N/A N/R + N/A N/A
Phase III N/R – N/R – N/R – – – – N/R –
Key:
+Conceptual approach articulated that should in theory address inequities but no supporting evidence to assess effect/impact on equity
+(+)Conceptual approach plus limited evidence (in terms of breadth and/or robustness) to suggest positive and/or negative impacts on equity
++Conceptual approach plus limited evidence (in terms of breadth and/or robustness) to suggest positive impact on equity\
+++Conceptual approach plus significant evidence (in terms of breadth and/or robustness) to demonstrate positive impact on equity
-(+)No conceptual approach mentioned but limited evidence (in terms of breadth and/or robustness) of positive and/or negative impacts on equity
−−No conceptual approach mentioned nor any evidence to illustrate impact on equity
N/RNot relevant (i.e. Strategy/policy/programme cannot directly mediate equity impact)












GAVI Board discussed the policy directions and imple-
mentation mechanisms to realize the Alliance’s mission.
The official record of those discussions contains two
policy directions of relevance for this review. First, the
GAVI Board at the time felt that selecting the ‘right’
technologies would ultimately reach previously un-
reached populations (“GAVI promotes the use of new and
safe technologies such as vaccine combinations and
monodose delivery devices that will facilitate reaching
the unreached”). Second, through collaboration with
other global health initiatives, the GAVI Board felt that
the Alliance would ensure the hardest to reach would be
vaccinated (“GAVI will collaborate with other initiatives
like Roll Back Malaria, African Program for Onchoceriasis
Control and Micronutrient Initiative to develop effective
campaign strategies to reach the most inaccessible popula-
tions”) [49].
Regarding selection of the right technologies: There is
evidence that during Phase I more Auto-Disable (AD)
monodose syringes were distributed to ensure safe vacci-
nations (by eliminating the risk of HIV/AIDS and other
blood-borne infections such hepatitis B, and hepatitis C
from dirty needles). Levels of distribution of these tech-
nologies rose from 24 million in 2001 to 471 million
units across GAVI countries by the end of 2005 [50].
Despite an independent evaluation of GAVI’s Injection
Safety Support, which funded the switch towards AD
syringes, there is no evidence to illustrate if the selection
of monodose delivery devices had a positive impact on
unreached or marginalized populations [25]. GAVI noted
in a progress report that by the end of Phase I, of all
countries approved for funds for hepatitis B vaccine, 31
(57 %) were using combination vaccines (e.g. a DTP-HepB
combination, or a DTP-HepB-Hib combination) com-
pared to just a handful prior to GAVI’s inception [50].
This suggests that during Phase I, GAVI had reduced in-
equities in access to vaccines between GAVI eligible coun-
tries. In theory, the convenience of additional antigens
without increasing the number of injections needed to vac-
cinate each child during the first year of life should have
prevented any detrimental effects on coverage and even
helped improve coverage within countries. However, no
evidence could be identified to illustrate a positive impact
of combination vaccines on within-country inequities.
Regarding collaborations with other initiatives: There is
evidence of GAVI Board-level discussions to foster broader
collaborations with other global health initiatives – in par-
ticular with Africa Measles Campaign and the Global Polio
Eradication Initiative – and these were supposed to have
both advocacy and financing components [51–53]. How-
ever, GAVI’s Phase I evaluation states that only limited
funding to the Africa Measles Campaign had been dis-
bursed at the end of Phase I and deemed it unlikely that
GAVI had significant impact at all during Phase I [17].
Given that at the formation of the Alliance it was
recognized that many countries were characterized by
stagnating or declining national immunization coverage
rates, GAVI did explicitly set out to address inequities
between countries in utilization of immunization ser-
vices. The specifics of those efforts are discussed further
below (in the section pertaining to 'Cash-based Sup-
port'). However, in aggregate the results of GAVI’s efforts
to address this dimension of equity were broadly posi-
tive. The Phase I evaluation points to the fact that “…
coverage rates increased in GAVI countries during the
course of Phase 1 – the DTP3 coverage rate increased
from 64 % to 71 %, HepB3 coverage rate increased from
16 % to 46 %, and Hib3 coverage rate increased from
1 % to 7 %” [17].
GAVI’s mission and milestones were heralded as the
cornerstones of a new approach that intended to im-
prove the infrastructure of vaccination [54] and address
within-country inequities in immunization [55]. How-
ever, concerns were raised that GAVI’s programs would
not benefit the most marginalized [56], and the absence
of specific polices/programs to address these inequities
(beyond selection of specific technologies and partnering
with other global initiatives) suggests that at the time,
the Alliance did not direct much attention or resources
to this issue. Still, GAVI’s Phase I evaluation suggests
some positive trends within GAVI countries over the
first phase of operations (i.e. reductions in inequities in
access to immunization). The evaluation assessed dispar-
ities in immunization coverage within 23 countries
where more than one Demographic and Health Survey
(DHS) had been conducted. The findings from the eval-
uators’ analysis illustrated that disparities in coverage
based on urban/rural residence and gender were reduced
during Phase I, with improvements correlated to total
GAVI funding (for both vaccines and cash-based sup-
port). However, the evaluators found no reduction in
disparities based on other important equity dimensions
(e.g. mother’s educational level or birth order). The eval-
uators did find evidence that wealth-based disparities in
immunization coverage decreased during GAVI Phase I,
but this was based on UNICEF Multi-Indicator Cluster
Survey (MICS) data from five countries only, and hence
was not statistically significant. The Phase I evaluation
also pointed to great variability on a country-by-country
basis concluding that despite GAVI’s overall achieve-
ments, the Alliance still needed to develop explicit and
effective approaches for facilitating support to countries
with low immunization coverage and/or large internal
disparities in coverage [17].
Phase II
In GAVI’s second phase of operations, an important step
forward was the development of a comprehensive
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strategic plan from the outset. Covering the period
2007-20109, GAVI’s strategic plan for Phase II provides a
detailed view on how best to deploy GAVI’s growing re-
sources [57, 58]. GAVI’s mission statement was amended
before Phase II and enshrined in the new strategy. The
revised statement was more incremental: “Saving chil-
dren’s lives and protecting people’s health by increasing
access to immunisation in poor countries” [58]. Despite
removing the aim to ensure child rights, universality,
and hence equity in final VPD outcomes from the mis-
sion statement, equity wasn’t entirely absent from the
Phase II strategy. Both between- and within- country
equity were captured within one of the GAVI operating
principles that accompanied the strategy; “Promote
equity in access to immunisation services within and
among countries” [59, 60].
Improving utilization of immunization services (as
measured by immunization coverage) in absolute terms
and towards levels observed in higher income countries
(as well as better-performing lower-income (GAVI-eli-
gible) countries) remained a priority for the Alliance, in
addition to its main goal of facilitating the introduction
of new vaccines in GAVI countries [58]. GAVI's strategic
goals, objectives and indicators for Phase II suggest an
intention to strengthen health systems as the means to
raise immunization coverage nationally with the assump-
tion that doing so would address geographic coverage
inequities within countries. However, due to a lack of
consistent and reliable sub-national (district level) cover-
age data, the within-country equity indicator was even-
tually dropped and the Alliance measured its success in
this phase of operations against national-level coverage
estimates alone [18]. In delivering on the Phase II strat-
egy, GAVI’s efforts were mixed. The Phase II evaluation
highlights that much of GAVI’s investments to
strengthen systems, and address program performance
and capacity could not be measured. Where progress
could be estimated (through modeled analyses), results
suggested that GAVI’s efforts to increase DTP3 coverage
may have only been significant for countries with initial
coverage of 65–80 % and not adequate to reach out to
the last 10–20 % of the unimmunized population [18].
While somewhat contradictory, the Phase II evaluation
also highlighted evidence that for some GAVI countries,
geographic equity of utilization of immunization services
improved since GAVI funding was introduced. That is to
say that the proportion of health districts reporting high
coverage (those estimated to have DTP3 coverage >80 %)
increased over the period of Phase II, while the proportion
of low coverage districts (those estimated to have DTP3
coverage <50 %) decreased over the same timeframe
among GAVI countries [18]. Neither strategies nor evi-
dence of impact are mentioned across other dimensions
of within-country equity in access to immunization.
Phase III
GAVI’s strategy for Phase III, was approved by the GAVI
Board in 2010. GAVI’s mission remained unchanged
from Phase II and as such, equity in final VPD outcomes
remained absent. However, the Phase III strategy was
explicit and consistent in articulating the Alliance’s
focus on within-country equity in two of the revised
operating principles10, a strategic goal-level target and
key performance indicator11 to measure progress (to
reduce inequities between socioeconomic groups in
immunization coverage within countries), as well as a
strategic objective12 [61, 62]. Most mentions of equity
in GAVI’s strategic framework are not specific to
either between- or within- country equity, access to
vaccines, GAVI funds or utilization of immunization
services.
GAVI’s Phase III strategy was augmented with an
integrated 2-year Business Plan13 to delineate how the
Alliance would support country governments to deliver
on the first biennium of the strategy (2011–2012) [62, 63].
In order to improve equity in access to immunization ser-
vices within GAVI countries, the Business Plan appointed
WHO to lead the majority of efforts to assist countries
with DTP3 coverage below 70 % and to develop coverage
improvement plans (including use of “Reach Every
District” -type strategies). In the second iteration of the
Business Plan, covering the second biennium of the strat-
egy, (2013–2014) the GAVI Board significantly increased
both the focus and resources channeled through multilat-
eral partners to provide technical assistance to address
inequities in access to immunization services within
countries. With these additional resources, UNICEF
committed to focus on ten countries (Nigeria, Yemen,
Congo Republic, India, Pakistan, Mozambique, Liberia,
Vietnam, CAR, and Madagascar)14 identified by the
GAVI Secretariat as having the greatest inequities in
immunization coverage. The aim of UNICEF’s efforts
was to identify the drivers of inequity and assist the
governments of these countries to develop plans to
address these inequities [64]. The GAVI Secretariat
also mentioned that it had commissioned a study in
Nigeria and other countries to explore issues of
“equity and trust” given the importance of these is-
sues in determining the effects and coverage of vac-
cines. It is not clear if this is the same or additional
to the work commissioned through UNICEF. [65]
These various country-specific initiatives and studies
are currently ongoing. It is too early to evaluate the
impact of GAVI’s focus to address inequities in access
to immunization services within countries, but a pre-
liminary readout of efforts to date is expected soon.
When complete and published, these efforts could
provide valuable insights into drivers of community
demand and barriers to equity in access to
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immunization services in GAVI countries facing large
within-country inequities in coverage.
The overall evaluation of GAVI’s results and impacts
in its third phase of operations will not be available for
some time. Full country evaluations to assess the impacts
and challenges of GAVI support in Bangladesh, India,
Mozambique, Uganda and Zambia commenced in 2013
and are expected to be completed in 2016. These
may offer the first tangible results of the third phase
of operations through an equity lens [28]. One limita-
tion for the Alliance is that these five countries are
far from representative of the full range of 74 coun-
tries where GAVI grants are being implemented. It
remains to be seen how GAVI will garner a more ful-
some and independent evaluation of its broad-ranging
efforts to address inequities in Phase III.
Vaccine priorities and New Vaccine Support (NVS)
Formation/Phase I
At the time of GAVI’s formation, despite the first
licensures of yellow fever (YF), Hepatitis B (HepB)
and Haemophilus Influenzae type b (Hib) vaccines in
1935, 1981 and 1986 respectively, these vaccines were
virtually absent from NIPs in most low and middle
income countries. As a result, there were large
between-country inequities in rates of vaccine-
preventable disease when comparing high income and
lower income countries [42, 66–71]. Accordingly,
GAVI focused its resources initially on reducing dis-
parities in access to HepB and YF vaccines and subse-
quently, Hib vaccines. At the outset, there was an
expectation that by the end of Phase I, GAVI would have
catalyzed almost universal access to HepB [72]. GAVI’s
Phase I evaluation completed in October 2008 suggests
that the Alliance was indeed very successful having made
huge strides to introduce HepB and YF vaccines. For ex-
ample, of the 71 countries eligible for HepB and Hib vac-
cine support over the course of Phase 1 from 2000 to
2006, the eligible countries approved for GAVI NVS rose
from 15 to 56 and 6 to 18 respectively [17].
At the end of Phase I, GAVI expanded its range of
investments to include some measles campaigns in
Africa – a region that had a disproportionately high
measles-related mortality. While these investments
could have addressed between-country inequities in dis-
ease burden, the fact that the investments occurred so
late in Phase I meant that no evidence of impact on final
outcomes was reported in the Phase I evaluation—or
elsewhere.
Phase II
GAVI’s second phase of operations was characterized by
expansion with more resources, initially through increased
bilateral donor commitments and then by the creation
and channeling of unprecedented levels of funding from
the Innovative Financing Facility for Immunisation
(IFFIm) [73]. These resources enabled GAVI to broaden
its vaccine portfolio. In addition to continuing the scale-
up of Hib-containing combination vaccines, pneumococ-
cal conjugate vaccines (PCV) and rotavirus vaccines (RV)
were added into the portfolio and NVS commitments
started to cover a broader range of vaccines. The stated
aims of these NVS programs were to reduce inequities
between GAVI and non-GAVI countries in access to these
newer vaccines, and to reduce in rates of the relevant vac-
cine preventable diseases [74]. GAVI’s Phase II evaluation
compares use of HepB and Hib vaccines between two
groups of countries: GAVI-eligible Lower-Middle Income
Countries (LMICs) versus those LMICs that were not eli-
gible for GAVI support (‘non-GAVI LMICs’). The evalua-
tors’ analysis illustrates that at the outset, a larger
proportion of non-GAVI LMICs were using these vac-
cines. Over the course of Phase I and particularly Phase II,
the gap between the GAVI and non-GAVI LMIC groups
decreased markedly [18].
The NVS programs in Phase II were also successful at
reducing inequities in access to new vaccines between
GAVI countries. By the end of 2009, the Phase II evalu-
ation points out that 89 % of GAVI countries with
endemic Yellow Fever had introduced YF vaccines, while
97 % and 83 % of all GAVI countries had introduced
HepB and/or Hib –containing vaccines [18].
The IFFIm resources also facilitated a series of one-
time investments in catch-up campaigns and replenish-
ment of emergency response stockpiles of YF vaccines
and Meningococcal A (MenA) conjugate vaccines. In
addition, IFFIm resources funded one-time investments in
measles, tetanus, and polio supplementary immunization
activities to aid measles elimination, maternal and neo-
natal tetanus elimination (MNTE), and polio eradication
efforts [73]. The stated aims of the elimination and eradi-
cation programs were broad – to reduce inequities in rates
of vaccine preventable disease and mortality between
countries, and specifcally within measles and MNT invest-
ment cases submitted to the GAVI Board, there is evi-
dence of explicit intent to make use GAVI funding to
address disparities within GAVI countries [75–77].
Modeled research illustrates that in providing access
to new vaccines against diseases like rotavirus, GAVI
vaccine support could benefit most the poorest groups
within eligible countries because these groups are at
greatest risk from infectious disease [78]. Of course,
elimination and eradication offer the ultimate in equity
improvement, protecting all people from specific
diseases [79]. While there is extensive documentation
available concerning progress over time with respect to
the global polio, measles, and MNT eradication/
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elimination efforts, no published evidence could be found to
illustrate the impact on equity dimensions of GAVI’s specific
contributions. That notwithstanding, the influx of resour-
cing and expansion of GAVI vaccine priorities in Phase II
should have positively addressed both within- and between-
country inequities in vaccine preventible disease burden.
While there is limited evidence to illustrate the causal
effects of GAVI investments on disease within a handful
of countries for routine vaccines like Hib [80, 81], global
burden of disease studies and estimates of child mortality
illustrate that certain low and middle income countries –
many of which benefit from GAVI support – saw marked
improvements in rates of vaccine preventable disease and
child mortality. These improvements extended into the
first decade of the new millennium which encompassed
GAVI’s phases I and II [82, 83].
Phase III
Through Phase III, GAVI has continued to accelerate in-
troductions of vaccines. All GAVI countries have now
introduced HepB and Hib vaccines in a pentavalent
combination, all YF endemic GAVI countries have intro-
duced YF vaccines into routine programs, and the ma-
jority of GAVI countries have introduced pneumococcal
vaccines [84]. As such, GAVI has done much to address
between-country inequities in access to these vaccines.
However, GAVI has gone further. In 2008, GAVI devel-
oped a vaccine investment strategy (VIS) based on an as-
sessment of the vaccine landscape that sought to identify
an expanded portfolio of vaccines that GAVI should
support. An Independent Review Committee of vaccine
and development experts reviewed portfolios of vaccines
against a series of seven criteria that included prioritizing
vaccines that disproportionately addressed socioeconomic
and gender inequities [85].15 The Board endorsed that this
VIS should be based on a strategic theme of maximizing
reductions in overall disease burden across GAVI coun-
tries [86]. In preparation for and during Phase III, two
rounds of VIS analyses prioritized vaccines (in addition to
those already in the GAVI portfolio) against the following
vaccine-preventable diseases: Cholera, Human Papilloma-
virus (HPV), Japanese Encephalitis (JE), Neisseria menin-
gitides group A (MenA), Rubella and Typhoid [87–92].16
Many of these vaccines prevent infections and diseases
that are more concentrated in certain regions (e.g. JE in
South East Asia, and MenA across the “meningitis belt”
spanning the 25 sub-Saharan countries) or that primarily
affect different gender and age groups (e.g. HPV causes
cervical in women in later life). As such, it has been noted
that by supporting these vaccines, the VIS positioned
GAVI well to address inequities in disease burden between
countries (i.e. inter-regional disparities in disease burden)
as well as inequities within- and between- countries (i.e.
gender disparities and inter-generational disparities) [93].
Others also point out that adding these vaccines to GAVI’s
portfolio should further reduce inequities between coun-
tries in access to vaccines that have benefits in both GAVI
countries and HICs (i.e. HPV vaccines) [94].
Beyond the VIS process, the GAVI Board also agreed
to complement the efforts of the Global Polio Eradication
Initiative (GPEI) by leveraging GPEI resources and GAVI’s
experience to facilitate widespread introduction of
inactivated polio vaccine (IPV) in almost all 73 of the
GAVI-eligible and graduating countries by 2017 [95].
Despite the significant expansion of GAVI’s vaccine pri-
orities, access to this wider array of vaccines at the coun-
try level has been slower than initially forecast . This is
partly because of GAVI’s prior funding constraints (pre-
cipitated by the Global Financial Crisis of 2007–2008) and
partly because of country readiness and national priority
setting [91, 96]. In addition, issues on the vaccine supply
side have conspired against rapid achievement of the im-
pacts outlined above, including supply constraints (e.g. for
Cholera vaccines), delays in regulatory approvals (e.g. for
JE vaccines), and delays in development of vaccines meet-
ing GAVI-defined specifications (e.g. conjugated Typhoid
vaccines) [97]. The GAVI Board took provisional decisions
to introduce Rubella, JE and HPV vaccines in 2008 yet the
first GAVI-funded Rubella (catch-up) campaigns and na-
tionwide introductions of HPV vaccines only commenced
in 2013, while the first nationwide introductions of GAVI-
funded JE (routine introductions) were scheduled in a
handful of countries for 2014 [98, 99]. Empirical evidence
to document impacts on between- and within- country in-
equities of GAVI’s expanded vaccine priorities in Phase III
are not yet available.
Since GAVI’s first phase of operations, the Alliance has
relied on an Independent Review Committee (IRC) that
provides a systematic process to review new proposals for
both NVS and cash-based support applications. Since
2010, the IRC has consistently recommended a greater
equity focus for GAVI programs (Personal communication,
John Grundy, 2015). IRC meeting reports that are available
online cover the period from November 2013 to present.
These reports delineate the need for improvements in NVS
applications to address within-country equity and gender
disparities [97, 100–103]. For example, in November 2013,
the IRC reviewed 31 NVS applications across a variety of
vaccines and found that 64 % of applications were ‘gender
blind’ or failed to recognize that gender is an essential de-
terminant of social outcomes impacting on projects and
policies. The reports also illustrate the IRC’s consistent
recommendations that GAVI strengthen application
guidelines. This has resulted in GAVI guidelines stressing
to eligible countries the importance of conducting more
systematic analyses of inequities and gender disparities,
and designing more progressive/pro-equity strategies for
new vaccine programming [102–106].
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With better guidelines to steer proposal development,
the IRC reports highlight the progress during Phase III.
The proportion of NVS and/or IPV applications that
identify equity barriers has increased from 12 % in 2012,
to 55 % in November 2013, and to 55 % in April 2014.
Concurrently, the proportion of NVS proposals that
described approaches to address identified equity
barriers increased from 8 % to 41 % to 55 % over the
same time period [97, 101]. Since the IRC now only
reviews plans for new GAVI grants rather than progress
and outcomes with existing grants, there is no commen-
surate evidence to illustrate the extent to which these
plans have been implemented and/or resulted in more
equitable outcomes.
Supply and procurement strategies
Formation/Phase I
A fundamental tenet underpinning the GAVI model
from the outset has been that the “poorest country seg-
ment should have the lowest effective price” to ensure
that vaccines would ultimately be affordable [49]. At the
third GAVI Board Meeting in the year 2000, this was
made more clear by the Alliance partner responsible for
vaccine procurement, UNICEF, in its ‘commitment to
vaccine supply and the vaccine industry’. In this commit-
ment, UNICEF acknowledged that it would procure vac-
cines for what it classified as the ‘Poorest Countries
Market’ (specifying that this market segment would be
defined by the GAVI eligibility criterion at the time); and
that it would separately purchase vaccines for 'Other
Country-specific Markets'. UNICEF requested that vac-
cine suppliers offer ‘significantly discounted prices’ for
the Poorest Countries Market, and in return, UNICEF
committed to not consider those as reference prices for
Other Country-specific Markets [107]. In essence, this
commitment proposed equity pricing (also known as
tiered pricing) – lowest pricing for countries supported
by GAVI, and the possibility of separate (often higher)
pricing for other countries. At the time, this was seen as
a ‘win-win’ for all parties, facilitating the market condi-
tions necessary to reduce the between-country inequities
in access to newer more expensive vaccines [84]. GAVI’s
Phase I evaluation suggests that the Alliance was moder-
ately successful in this regard although prices did not de-
cline as quickly as the GAVI Board had hoped [17].
Phase II
At the end of Phase I and in preparation for Phase II,
the Alliance developed an overarching supply and pro-
curement strategy with a particular focus on Hib- and
HepB-containing vaccines [108]. This was based on an
in-depth analysis of the evolution of the vaccine supply
landscape that was commissioned by GAVI and con-
ducted by the Boston Consulting Group [109]. The
analyses brought into focus the complexities of the
vaccine market and nuances of the interactions between
pricing and a variety of other factors such as demand,
competition, production costs, and contracting terms.
With the focus on the markets for the two newest vaccines
in GAVI’s purview (HepB, Hib) at the time, GAVI’s new
supply strategy detailed a need for sufficient and sustain-
able supply, as well as affordable and sustainable prices, for
eligible countries. However, the notion of tiered or equity
pricing is not mentioned. The Phase II evaluation is silent
on all between-country equity impacts of the Alliance’s
supply and procurement strategy (except for the acceler-
ated adoptions of HepB and Hib vaccines among eligible
countries as described under ‘Vaccine Priorities’ above).
Phase III
While tiered pricing was viewed during GAVI’s initial
phases of operation as a necessity and pre-requisite for
reducing inequities in access to new vaccines/antigens
between GAVI countries and wealthier countries, more
recent discourse has provided a new and more critical
narrative. To some, the global tiered pricing structure
for vaccines brought about by the formation of GAVI
(that guaranteed the lowest prices for GAVI countries
procuring through UNICEF) has created unintended in-
equities between countries GAVI countries and ineligible
Middle Income Countries (MICs). It is argued that many
ineligible MICs that do not benefit from GAVI funding
nor access to the lowest prices cannot access newer vac-
cines/antigens such as PCV, RV and HPV vaccines [110,
111]. According to this narrative, tiered pricing is at the
heart of the problem. By contrast, advocates of tiered pri-
cing and notably the GAVI Secretariat’s current CEO have
suggested that if the mechanism were extended, it could
offer a solution to reduce those same between-country in-
equities [112]. Evidence to conclusively justify either per-
spective is patchy or circumstancial. However, as noted by
GAVI’s revised Supply and Procurement strategy for its
third phase of operations, GAVI countries continue to
benefit from the practice of tiered pricing and lowest prices
worldwide [113]. Efforts to secure more consistently af-
fordable prices for MICs (including countries that have
graduated from GAVI support, and ineligible countries)
has been a work in progress with some tension regarding
whether this lies within or beyond the scope of GAVI [98].
Country eligibility policies and program filters
Formation/Phase I
Perhaps the most explicit way in which equity between
countries was considered during GAVI’s formation and
first phase of operations was in the definition of GAVI’s
eligibility policy. The Phase I eligibility policy was based
on each country government’s ability to pay for vaccines
for use within their NIP – those countries with the least
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ability to pay would be eligible. Average Gross National
Product (GNP) per capita was used as a proxy for ‘ability
to pay’ and a threshold of US $1,000 or less was applied
to the World Bank’s per capita income data for the
financial year 1999 to determine the list of eligible coun-
tries for GAVI’s first phase of operations [17, 114]. While
documentation to explain the motivations for the policy
design is sparse, the eligibility threshold was based at least
in part on the resources available to GAVI at the time of
its formation (Steve Landry: Personal communication;
2009) as well as a desire by GAVI’s architects to create an
“IDA-like” list of countries (i.e. a list of countries similar to
those that could access the World Bank’s International
Development Association (IDA) loans and grants) [115].17
GAVI’s eligibility criterion and threshold in Phase I
generated a list of 74 countries that would be eligible for
GAVI support.18,19 Based on World Bank country classi-
fications at the time, that list comprised 63 Low Income
Countries (LICs) as well as 11 LMICs. The inclusion of
LMICs from GAVI’s inception was an implicit acknow-
ledgement: first that inequities in access to new vaccines
were not neatly aligned with World Bank income classifi-
cations, and second, that all LICs and at least some LMICs
required development assistance to alleviate disparities in
immunization as compared to higher income countries.
Despite trying to improve access to new vaccines/anti-
gens and utilization of immunization services among the
lower income countries, the imposition of an eligibility
threshold based on a single (per capita income-based)
criterion naturally created inequities between eligible
and ineligible countries. LMICs immediately above the
US $1000 threshold in the financial year 1999 (e.g. the
Philippines that had a GNI per capita estimate of US
$1030) were unable to access GAVI support in Phase I
and were probably not appreciably better able to pay for
and access new vaccines than those countries just below
the threshold (like Bolivia with a GNP per capita of US
$970) [116].20
During Phase I, GAVI also instituted ‘program filters’
to determine which of the eligible countries could access
particular kinds of GAVI support. Eligible countries
attaining national coverage of the third dose of
Diphtheria-Tetanus and Pertussis (DTP3) of less than
50 % were not permitted to apply for GAVI’s NVS
grants21 with the exception of YF vaccine grants. The
underlying rationale was that it would not be efficient to
invest GAVI funds on new vaccines for countries unable
to immunize at least half of their childhood populations
with existing routine vaccines. Accordingly, it was felt that
those countries with low immunization coverage should
focus on improving immunization program performance
before adding new vaccines such as HepB to their NIPs
[117]. Countries with national DTP3 coverage rates of
more than 80 % were not eligible for cash-based support22
to strengthen their immunization programs, presumably
based on a notion of that these countries would be less
able to markedly benefit from these small investments.
When first instituted, 14 of the 74 GAVI-eligible coun-
tries, including Timor-Leste (once it became eligible),
were unable to access NVS while 22 eligible countries
were unable to access cash-based support. [115, 118] The
motivation driving the creation and imposition of these
filters was efficiency. As a result, efficiency was seemingly
traded off against between-country equity as the NVS
filter in particular prevented those GAVI countries in
greatest need from accessing new vaccines/antigens.
By contrast, countries applying for YF NVS grants
were exempted from the DTP3 program filter on
grounds that the eligible countries affected by the disease
were “the poorest of the poor… and have the weakest
immunization systems …” [119]. In a sense, the exception
of YF vaccines from program filters promoted vertical
equity between eligible countries by lowering the thresh-
old to access GAVI resources (for YF vaccines) for those
countries deemed to have greater needs.
Phase II
Prior to the start of GAVI’s second phase of operations,
GAVI’s eligibility policy was updated with the latest (GNI
per capita) reference data published by the World Bank
for the financial year 2004. However, reliance on a sole eli-
gibility criterion continued, and the US $1,000 eligibility
threshold was left unchanged [120]. This policy update
decreased the number of eligible countries to 72: four
countries (thePeople’s Republic of China, Turkmenistan,
Albania, and Bosnia and Herzegovina) were now above the
threshold and were reclassified as ineligible for new GAVI
support, and one country (Kiribati) fell below the threshold
and became eligible for the first time from 2006 onwards
[121]. A further update to GAVI’s eligibility policy was con-
sidered during Phase II, but the GAVI Board decided not
to revise the eligibility policy largely to maintain predict-
ability of financing support [122, 123].
The level of the DTP3 filter was left unchanged
despite the fact that by 2006 only two of the eligible 72
countries (Chad and Somalia) had national DTP3
estimates according to WHO/UNICEF below 50 %.
From the perspective of between-country inequities in
access to new vaccines/antigens, the revised country eli-
gibility and the unchanged DTP3 filter policies for Phase
II resulted in marginally fewer countries being allowed
to introduce new vaccines; but, of those that were eli-
gible, the vast majority were able to benefit from access
to GAVI’s expanded suite of new vaccines and cash sup-
port. A modeled analysis conducted during Phase II cov-
ering a period prior to GAVI’s inception and through the
middle of Phase II suggests that GAVI countries had ac-
celerated decisions to adopt Hib-containing vaccines as
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compared to non-GAVI (ineligible) countries [124].
More recent evidence suggests that GAVI’s success in
assisting eligible countries access to new vaccines/anti-
gens inadvertently increased between-country inequities:
Specifically, because of GAVI’s success in facilitating
new vaccine introductions in eligible countries, by the
end of Phase II, ineligible MICs lagged behind their eli-
gible country counterparts [125, 126].
Phase III
In 2009, GAVI revised its eligibility policy once again –
now considering the policy objectives, criteria, data sources
and thresholds that generate the list of eligible countries.
One of the most significant weaknesses of the previous
policies had been the infrequency of the updates, particu-
larly of the underlying reference data. The eligibility criteria
(GNI per capita as a proxy for ability to pay for vaccines)
and the threshold (GNI < US $1,000 per capita) had been
defined data for the financial year 1999 and held constant
throughout both Phase I and II, while the reference data
for the financial year 2003 (published in 2004) had been
used throughout Phase II. By holding the threshold and
reference data constant for five years, GAVI had created a
series of between-country inequities in access to GAVI re-
sources when viewed through the lens of the current aver-
age per capita incomes.23 The Alliance was keen to avoid
such inequities going forward and thus the Board approved
an updated and more dynamic policy [126].
During the eligibility policy development process at
the time, an issue central to addressing between- and
within- country inequities was discussed; namely, whether
GAVI’s eligibility policy should generate a list of the ‘poor-
est countries’ or a list of the countries that had the largest
number of ‘poor people’.24 This discussion came about in
large part because it was noted that within several large
middle income (and ineligible) countries – notably Brazil,
China, the Philippines, South Africa –a significant propor-
tion of the population were living in poverty or extreme
poverty. More often than not, substantial amounts of these
populations remained unimmunized or under-immunized
with GAVI-supported vaccines/antigens. In many instances
the size of these impoverished and/or underserved groups
within ineligible MICs was observed to be as large as- or
larger than- the total populations living in many GAVI
countries. It was also highlighted that several MICs that
had never been GAVI-eligible lagged behind GAVI coun-
tries in terms of adoption of new vaccines/antigens.
GAVI’s eligibility policy architects for Phase III noted
these valid concerns but also that there were political,
operational and pragmatic reasons for GAVI to maintain
an eligibility policy based on countries, rather than people
as the unit of classification. The policy designers recog-
nized that it would be difficult for GAVI to accept applica-
tions from country subunits (e.g. state governments or
semi-autonomous regions) given that vaccine adoption deci-
sions and public investments in health more generally are
sovereign decisions (or at least centrally determined) and to
allocate cash or in-kind resources (e.g. vaccines) to country
subunits would distort fiscal federalism policies [128]. On
the supply side, tiered pricing policies defined by vaccine
manufacturers generally use nation-states as the unit of
measure [129, 130]. Looking at GAVI operations, all of
GAVI’s programs had been and still are, set up to receive ap-
plications for NVS or health systems strengthening (HSS)
support from national governments. For example, each ap-
plication for GAVI support requires Ministers of Health and
Ministers of Finance to serve as co-signatories [131, 132].
From a pragmatic standpoint, in order to isolate countries
with large sub-populations living in poverty, one would need
to rely on demographic surveys (i.e. DHS, MICS). However,
such survey data are not available for all GAVI countries,
are conducted infrequently (e.g. at best every 2–3 years) and
are conducted in different years for different countries. All
this would mean that in a given year, data would not be
comparable across countries nor consistently up to date.
Given GAVI’s desire to have a new policy that was dynamic,
such measurement challenges made reliance on survey data
far from ideal as the underpinnings of an eligibility policy.
Finally, GAVI’s stated mission at the time was “Saving
children’s lives and protecting people’s health by increasing
access to immunisation in poor countries” [133]. Weighing
all these facts, GAVI’s Programme and Policy Committee
(PPC) confirmed that GAVI’s new eligibility policy should
“(f)ocus on poorest countries (rather than the poorest people)
using consistent, reliable and valid indicators” [134]. The
eventual policy approved by the Board continued to rely on
GNI per capita as the indicator to identify the countries with
lowest average incomes. However, the US $1,000 threshold
was inflation-adjusted to US $1,500 and thereafter updated
annually along with the underlying reference data (i.e. to
hold the threshold constant in real terms) thereby creating
a dynamic list of eligible countries throughout Phase III
[135, 136]. Over the course of Phase III, no new countries
have become eligible, however a growing list of 16–20
countries have entered the graduation process restricting
access to newer vaccines/antigens to a subset of the coun-
tries that were eligible at the outset of Phase III.
Despite maintaining the eligibility policy throughout
Phase III, the debate concerning GAVI eligibility has con-
tinued to divide the GAVI Board throughout this phase of
operations. This has been fueled by a variety of equity
concerns. Questions have been raised about the fairness of
focusing GAVI’s efforts on the poorest countries versus
poorest people, the fairness of limiting access to funding
for newer vaccines/antigens to GAVI eligible but not
GAVI graduating countries, and the fairness of restricting
access to the lowest vaccine prices to GAVI countries, but
not extending those prices to ineligible MICs [137–144].
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As part of the revised country eligibility policy for
Phase III, the GAVI Board approved raising the level of
DTP3 coverage filter for countries to be eligible to apply
for new vaccines support from 50 % to 70 %. The Board
agreed to raise the bar contingent on efforts being devel-
oped to improve coverage and strengthen systems in
countries with DTP3 less than 70 %25 [135, 136]. The
following justification for these changes were provided:
“On equity, this filter signals to weak performers that
they need to increase coverage of traditional vaccines
(and presumably reach harder-to-reach groups, who tend
to be poorer) before expanding coverage to new vaccines”
[145]. The implicit assumption being that raising na-
tional coverage would address internal inequities within
countries. As with earlier iterations of this policy, on
grounds of efficiency the imposition of the filter continued
to make it difficult for those countries with low
immunization coverage to access some of the newer vac-
cines, exacerbating inequities between GAVI countries in
access to these vaccines/antigens.
Large countries and budget cap policies
Formation/Phase I
Recognizing that GAVI’s budget was particularly limited in
its first phase of operations, and that not all countries under
GAVI’s eligibility threshold were equal, in 2001 the GAVI
Board capped resource allocations at US $40 million to the
three eligible countries with the largest overall populations
(China, India, and Indonesia) for the remainder of Phase I
[146]. In reaching that decision, the GAVI Board recognized
that those three countries had large economies and import-
ant domestic vaccine manufacturing capacity. As such, it was
thought that GAVI should give these three large countries
different consideration than other countries. This created
another between-country equity dimension with respect
to access to GAVI resources, this time between the largest
three countries and other eligible countries [146].
In hindsight, these budget caps had a mixed impact on
inequities in access to new vaccines, immunization services
and GAVI resources more generally. The independent
evaluation of GAVI’s Phase I delineates the expected total
5-year GAVI commitments by country across the various
forms of GAVI support available at the time of the evalu-
ation. The three large countries with budget caps (China,
India, and Indonesia) were allocated commitments (i.e.
GAVI NVS and cash-based support grants) almost equiva-
lent to their allotted budgets (GAVI commitments to
China, India, and Indonesia in Phase I are listed as US
$39-40 million). In contrast, there were 13 significantly
smaller countries (as measured in total population terms)
with equivalent or larger allocations. These countries were
Angola, Bangladesh, DR Congo, Ethiopia, Ghana, Kenya,
Malawi, Nigeria, Pakistan, Tanzania, Uganda, Yemen, and
Zambia. GAVI commitments in Phase I to each of
these 13 countries were between US $39-155 million des-
pite the fact that all had fewer unimmunized children, and
in some cases, lower levels of infant mortality than any
one of China, India and Indonesia [17]. This suggests that
during Phase I, the budget caps negatively affected hori-
zontal inequities between GAVI countries..
Comparing how two of these large countries (China
and India) used the capped GAVI budgets allocated to
them illustrates that GAVI’s approach to large countries
may have had varied effects on within-country inequities.
A recently completed independent evaluation of the GAVI
support of China's HepB vaccine introduction illustrates
that GAVI support was very successful in catalyzing the
vaccine’s introduction nationally [148] and addressing
within-country inequities [21, 149]. Since the Government
of China used GAVI resources exclusively to target the
introduction in the poorest areas of the country with the
worst health statistics (the 12 Western Provinces and the
most impoverished counties of the 10 Central Provinces),
GAVI resources were targeted progressively to address
within-country inequities in disease burden, and accord-
ingly “eliminated socioeconomic inequities in vaccination
coverage” [150]. By contrast, in India, where much of the
budget made available by GAVI in Phase I was also used
to catalyze HepB vaccine introduction, the Government of
India (GOI) chose to target 15 metropolitan cities and 33
districts evaluated to have a high immunization coverage
(>80 %) at the time. While this approach encompassed
slum populations in some cities that might be at higher
risk of HepB, the focus on high coverage districts on
grounds of efficiency may have exacerbated within-
country inequities in access to the new vaccine, particu-
larly affecting the rural poor [151, 152].
Separate from the budget caps, in its 2004–2005 strategic
framework, GAVI indicated an intention to strengthen
routine immunization and coverage in seven eligible
countries with a large number of unvaccinated chil-
dren (Bangladesh, India, Indonesia, Nigeria, Demo-
cratic Republic of Congo, Pakistan, and Ethiopia).
This intent recognized that progress towards the glo-
bal development goals at the time (e.g. Millennium
Development Goals—MDGs, Global Immunization Vision
and Strategy—GIVS goals) would depend on significant
improvements in those counties. To help the governments
of these large countries reach unreached and underserved
children with new vaccines and immunization services
(and hence address within-country inequities ), GAVI re-
sources were provided to WHO and UNICEF in order to
strengthen their own capacity, the capacity of other in-
country partners, as well as the ability of health systems in
those large countries to effectively target services to un-
reached populations. The intended outputs from this
funding were analyses of the barriers to access, and agreed
action plans that would be endorsed by national
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Interagency Coordinating Committees (ICCs). In addition,
GAVI committed to establish specific policies to help the
countries in question. GAVI documents at the time expli-
citly noted that these plans and policies should draw upon
lessons learned from the accelerated disease control
(ADC) initiatives such as those focused on polio eradica-
tion, measles control, and MNTE that were active in these
large countries [153–155].
A significant weakness is that there is limited docu-
mentation available to describe the results from these
efforts. It is clear that WHO and UNICEF assisted the
seven large countries to analyze the barriers and possible
solutions to accelerating immunization coverage and
agreed action plans with ICCs by 2004. However, the
extent to which these plans were implemented, and the
outcomes of these activities are less clear [156]. Later
iterations of GAVI’s work plan suggest that these efforts
were deemed to at least be partially successful in some
countries or at least no longer needed since the scope of
the efforts were pared down from seven to four of the large
countries where the Alliance focused its efforts [157].
Phase II
Early in Phase II, the GAVI Board reviewed support to
large countries recognizing that the previous definition
of ‘large countries’ had been based on the total popula-
tion of the country rather than the birth cohort. This
was despite the fact that GAVI’s support was largely
directed towards subsidizing childhood vaccines. This
definitional detail meant that Indonesia had been classi-
fied as a large country by GAVI, and hence had a capped
budget allocation despite having a smaller birth cohort
than that of several other countries not classified under
GAVI’s budget cap policy as ‘large countries’ (e.g. Nigeria
and Pakistan). Therefore, other smaller countries with
fewer unimmunized children had accessed larger
amounts of GAVI support than had been made available
to Indonesia or any of the countries classified as large
countries. On the basis of these between-country equity
arguments, the GAVI Board removed the budget cap for
Indonesia and increased the cap for the other
remaining large country, India to US $100 million for
Phase II [59, 158–160]. A year later, India’s budget
cap was increased further to US $350 million following
several rounds of negotiation with the GOI which provided
the GAVI Board sufficient assurances that the GOI was
strongly committed to introduce other new vaccines/anti-
gens (i.e. Hib-containing vaccines) and to scale up domes-
tic allocations for India’s NIP more generally [161, 162].
The relaxing of GAVI’s budget cap policies increased
the ability of large countries to access GAVI resources
and ameliorated between-country inequities in access to
GAVI resources. However, the manner in which India,
the largest GAVI country (annual births), continued to
approach GAVI support (focusing GAVI resources on
the best performing areas within the subcontinent)
potentially continued to exacerbate within-country
geographic inequities in access to new vaccines. As with
the GOI’s initial applications to GAVI for HepB vaccine
support in Phase I, the GOI’s Phase II applications for ex-
tended HepB support and for the planned introduction of
Hib vaccine/antigen targeted GAVI resources to those dis-
tricts with high routine immunization coverage. Thus, the
GOI provided the new vaccines to those populations
already best-served by the NIP on efficiency grounds26
[163, 164]. While the aim was to scale these pilot programs
up across the country thus reducing geographic inequities,
nationwide use of HepB and Hib in India's NIP had yet to
materialize at the time of this systemmatic review.
Phase III
In GAVI’s eligibility policy for Phase III, the GAVI Board
endorsed that a new budget cap be considered for India
covering the period 2012–2015 and then revisited there-
after subject to funding availability [135, 136]. However, a
new budget cap was never defined and never discussed by
the GAVI Board. While no documentation could be found
to support the motivations for the lapse in policy, it may
be related to the fact that soon after the aforementioned
Board decision on eligibility, donors committed US $4.3
billion to the GAVI Alliance – exceeding the announced
target of US $3.7 billion that needed to be raised - at
GAVI’s first Pledging Conference [165]. Therefore,
whether by design or default, GAVI has not formally de-
bated nor actively instituted budget caps for any eligible
and large countries in its third phase of operations.
Cash-based support for program/system strengthening
Formation/Phase I
Given that GAVI’s DTP3 program filter made it more
difficult for countries with low immunization coverage
(and often with sizable within-country inequities) to
benefit from GAVI-funded vaccines, GAVI created a
funding ‘window’ to which eligible countries could apply
to access so-called 'cash-based support' to help finance
investments in their routine immunization programs. It
was hoped that this cash-based support - which eventu-
ally became known as GAVI’s Immunization Services
Support (ISS) -would catalyze immunization coverage
improvements by making continued funding conditional
upon improvements in performance and quality
immunization coverage data. In order to operate such
that GAVI-funded programs were “country driven”,
GAVI did not specify how its cash-based support should
be used beyond that it was spent by/on a country’s NIP
[166]. Reviews of GAVI programming during Phase I
noted that the reward system employed by ISS might en-
courage countries to use funds to raise overall coverage,
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but not necessarily to address inequities in access to
immunization services within countries [167–169]. One re-
view noted that of the countries that had used ISS funds in
the first year of the program, only one – Tanzania – had
taken the opportunity to allocate funds to address in-
country inequities, by targeting it towards low coverage dis-
tricts [167]. Evidence produced later suggests that ISS had a
positive effect on coverage in those countries with low levels
of national immunization coverage (i.e. DTP3less than 65 %
at baseline) [168], but subsequent analyses suggest that the
performance-based payment system that underpinned the
ISS program may have inadvertently encouraged service
providers to over-report immunization coverage. This called
into question the underlying data used to assess the effects
on coverage and equity of this program [170]. Data chal-
lenges notwithstanding, two independent evaluations of
GAVI’s ISS funding confirm mixed results [19, 20]. The sec-
ond and more comprehensive evaluation conducted in 2007
and reviewing the experience of Phase I found that while
the GAVI's cash-based support did positively affect national
immunization coverage, the funding was less effective at im-
proving national DTP3 coverage in the group of countries
defined by the World Bank at the time as ‘Low Income
Countries Under Stress’ (LICUS countries) as compared
with the effects in non-LICUS countries. Furthermore,
the evaluation found no association between ISS funding
and observed improvements in geographic equity of
immunization coverage within countries. As a result, one
of the evaluation’s key recommendations was for GAVI to
revise the ISS mechanism, emphasizing the importance of
considering, among other things, equity objectives [20].
Phase II
One significant change to GAVI’s operations in Phase II
came with the recognition that achieving improvements in
immunization coverage would be dependent on having
strong underlying health systems. Accordingly, and based
on the findings of a series of studies conducted between
2003 and 2005 [171–173], the GAVI Board agreed to invest
an initial US $500 million over a 5-year period in a new and
broader form of cash-based support that became known as
the HSS funding window. GAVI's HSS funds were intended
for eligible countries to address system constraints ultim-
ately to improved immunization coverage and health care
delivery. Again, GAVI did not specify how countries had to
spend this money, and allowed country governments to dir-
ect these resources beyond immunization programs alone
[160, 174–176]. The GAVI Board set resource allocation
formulae to determine the envelope of HSS funds for each
country as follows: Countries with an annual GNI per
capita greater than US $365 had access to an envelope of
resources equivalent to US $2.50 per surviving infant per
year; countries with an annual GNI per capita less than US
$365 had access to US $5.00 per surviving infant per year.
As noted in a paper to the GAVI Board, “… the allocation
of funds is based on number of births with special consider-
ation for the poorest countries based on level of GNI per
capita, thereby enhancing equity” [175]. The original HSS
allocation formula was designed first and foremost to
ensure vertical equity in access and distribution of GAVI
resources for HSS. What’s more, the original HSS guide-
lines produced by the GAVI Secretariat did not offer any
guidance to countries on focusing HSS funding applica-
tions on pro-equity strategies to address within-country
inequities [177]. Unsurprisingly, the subsequent independ-
ent evaluation of GAVI’s HSS funding through 2008 states
that HSS proposals did not have a clear or visible focus to
address the specific needs of underserved groups, al-
though many of the proposals targeted sub-national bot-
tlenecks and/or underperforming districts that included
high presence of hard to reach population groups [22]27
[178]. The 2007 and 2009 revisions of the GAVI HSS pro-
posal guidelines were more explicit with respect to ad-
dressing inequities in access to immunization services.
They encouraged governments applying for HSS funds to
consider targeting hard to reach groups and marginalized
populations as well as addressing issues of within-country
inequity in the provision of immunization services (in-
cluding those that created gender inequalities) [22, 179,
180]. As a result, there is some limited evidence that
GAVI-funded HSS grants in the latter stages of Phase II
targeted sub-national barriers to access, although evidence
to illustrate concrete outcomes (intermediate or final)
related to these efforts are not available [180].
In 2006, the GAVI Board also approved a new pilot
funding platform in order to strengthen the coordination
and representation of Civil Society Organizations (CSOs)
within the implementation of GAVI HSS grants and
national immunization programming more generally.
The platform funding was piloted in 10 countries28
[181–183]. It was envisaged at the outset that CSOs
were, in most eligible countries, important for increasing
access to immunization in general. An independent evalu-
ation of the pilot program found that in some countries
where the public sector was functioning well and was man-
aging the principal mode(s) of immunization delivery
(notably Ethiopia and Pakistan), CSOs had an important role
in delivering vaccines to hard-to-reach areas or neglected
population groups, thus helping to remediate within-
country inequities in coverage [24]. While the approach was
piloted in Phase II, an assessment of the broader (equity)
impacts particularly on outcomes is not available.
As aforementioned, GAVI’s Phase II evaluation highlights
that GAVI countries improved more in terms of geographic
equity of access to immunization services since GAVI fund-
ing had been introduced. However, the evaluation also
notes that there was no obvious relationship between
GAVI’s cash-based support in Phase II and improvements
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in geographic equity indicators [18]. Thus, while observed
improvements may have been related to the efforts of the
Alliance, they cannot be attributed to GAVI funding.
Phase III
GAVI’s strategic plan for 2011–15 refocused HSS on
immunization outcomes to “contribute to strengthening
the capacity of integrated health systems to deliver
immunization by resolving health systems constraints,
increasing the level of equity in access to services and
strengthening civil society engagement in the health sec-
tor” [61, 144]. Thus, at the strategic level, equity and the
importance of CSOs was made far more explicit as was
the fact that HSS investments ultimately ought to dem-
onstrate a results chain back to immunization outcomes.
Building on the findings from the HSS evaluation con-
ducted during Phase II [22], GAVI published guidance to
help countries applying for HSS funding to consider gender-
related barriers to access (i.e. social and cultural norms that
influence men’s and women’s roles and that ultimately im-
pact access to immunisation services) [184]. GAVI noted
that HSS funds could be used to identify– through special
studies or investigations – gender-related barriers in the na-
tional health system and within the immunisation services.
HSS funds could also be used to remove such barriers
through capacity-building of health services and community
staff and special interventions. No evidence could be found
to demonstrate the extent to which GAVI's HSS funds have
subsequently been used to address these inequalities and
disparities or the extent to which HSS investments have re-
sulted in reducing such barriers.
In November 2011, the GAVI Board decided that
GAVI’s HSS funding would be consolidated into a single
window (i.e. no separate windows for HSS and ISS, nor
separate applications for funds directed to governments
versus to CSOs). The revised HSS window required that
all countries be approved for the HSS performance-
based funding (PBF) component. As with GAVI’s HSS
funding in Phase II, the total funding envelope for each
country (referred to as ‘country ceiling’) continues to be
based on the country’s GNI per capita and total popula-
tion—i.e. the amount of cash-based support is still deter-
mined with the aim of ensuring equity (between eligible
countries) in access to GAVI resources [137, 185]. How-
ever, in addition to a lump sum, PBF payments are de-
termined based on progress against the national DTP3
coverage level at baseline. For countries with national
DTP3 coverage <70 % or 70–89 % at baseline, perform-
ance payments are dependent on coverage improve-
ments in DTP3 and the first dose of measles containing
vaccines (MCV1). For countries with national DTP3
coverage ≥90 % at baseline, performance payments are
split between maintaining national DTP3 coverage levels
and minimizing within-country geographic inequities in
coverage (i.e. specifically ensuring that 90 % of districts
have ≥80 % DTP3 coverage) [186, 187]. This is the first
and only explicit example of a GAVI resource allocation
mechanism that is designed to channel resources to
eligible countries based on grounds of within-country
inequities in utilization of immunization services. Des-
pite this decision taken in 2012, GAVI has yet to publish
any reports summarizing the scheme’s resultant impacts
on coverage and equity. However, one case study has
been published delineating the effects of GAVI’s PBF-
based HSS in rural Cambodia. This notes that the GAVI
support did bring about an increased volume of services
to underserved rural areas along with strengthened
financial and operational management. However, the
authors note that the PBF scheme did not help ensure
high quality of these additional services [188].
GAVI’s IRC reports highlight the limitations of HSS
applications submitted during Phase III with respect to
inequities and gender disparities within countries. Notable
deficiencies flagged by the IRC include: limited identi-
fication of underserved groups and the equity/gender
barriers that hinder the groups’ access; limited articu-
lation of strategies to address these barriers and/or
monitoring frameworks to track progress to ameliorate
the situation; lack of CSO involvement in development of
HSS proposals to ensure underserved are not overlooked;
insufficient consideration of how CSOs can help address
disparities particularly in conflict situations; insufficient
consideration of how integration with other programs can
help address inequities [97, 100, 102, 103]. Given that the
IRC often requests resubmissions or clarifications before
recommending the GAVI Board to fund country pro-
posals, the independent reviews do likely sharpen country
plans to address inequities and gender disparities
within countries using HSS funds. However, as afore-
mentioned with IRC reviews of NVS proposals, there
is no commensurate evidence available as yet to illus-
trate the equity outcomes from GAVI’s investments.
While not directly about GAVI’s PBF scheme nor
specifically about GAVI’s HSS investments in Phase III
alone, one ethnographic case study of the evolution of
GAVI’s role in HSS is considerably more critical. The au-
thor states that the most important effect of the creation
of GAVI’s HSS window has been to strengthen the power
of vertical global health initiatives like GAVI in defining
the global health agenda. Furthermore, the paper suggests
that GAVI’s expanded role in HSS has legitimized some of
the practices (e.g. private financing, a narrow focus on
measurable health outcomes) that the author argues have
contributed to decimating poor countries’ health systems
[189]. While the author does not explore how GAVI’s
efforts have helped or hindered between- or within- coun-
try inequities in access, the inference is that GAVI’s
involvement in HSS has not been wholly positive.
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Vaccine introduction grants and policies
Formation/Phase I
Early experience with vaccine introductions during Phase
I led GAVI to provide countries with financial resources
to facilitate introductions (e.g. in order to upgrade
immunization delivery infrastructure, such as replacing an
ageing cold chain or training new health staff ). Specific-
ally, eligible countries were provided with another form of
cash-based support, as a one-time cash grant of US
$100,000 at the time of introducing each new GAVI-
supported vaccine [190]. In this regard, resources to sup-
port vaccine introductions was shared equally in absolute
terms among all countries planning vaccine introductions.
A review of experience with vaccine introduction grants in
Phase I recognized that the lump sum award was “…not an
equitable way to support new vaccine introduction activities.
Given widely varying population sizes in GAVI-eligible
countries, not all countries benefited equally from this cash
award… Allocations ranged from a maximum of US $19.0
per infant in Sao-Tome and Principe, to a minimum of less
than US $0.01 per infant in Pakistan” [191, 192].
Phase II
To address the inequities (between small and large GAVI
countries) in access to GAVI vaccine introduction grants
(VIGs) that were inherent within the original policy, the
policy was revised policy. The new policy stipulated that
countries should be provided an amount (US $0.30) on a
per infant basis with a minimum absolute award value
(US $100,000) for the smallest countries . Recognizing
that the full extent of introduction costs was unknown –
particularly for newer vaccines against rotavirus and
pneumococcal diseases that GAVI was planning to sup-
port – the figure of US $0.30 per infant was derived based
on an adjusted US $100,000 award divided by the median
number of infants in the GAVI countries (excluding
India).The minimum award was set at the levels of the
grants in Phase I (i.e. US $100,000) [192].
It would not be until GAVI’s next phase of operations
when additional data on estimated costs of introduction
would become available and the sufficiency of the VIGs
could be tested. With hindsight, GAVI’s VIGs were likely
insufficient to cover needs (G. Gandhi, P. Lydon,
E. Furrer, H. Saxenian, A. Nguyen: Costs of Introducing
Childhood Vaccines in Low and Lower Middle Income
Countries: Inputs for GAVI Policy on Introduction Grant
Support to Countries, in press). Funding constraints may
have hindered many countries’ ability to harness the
opportunity of a new vaccine introduction to improve
vaccination coverage and/or reduce within-country in-
equities in access to vaccines, although existing evidence
is unsufficient to confirm this hypothesis [193–195]. In
any result, GAVI’s guidelines for new vaccine introduction
applications in Phase II were largely silent on the need
for pro-equity programming in new vaccine introduc-
tions [104].
Phase III
GAVI updated its VIG policy in 2012. As with the VIG pol-
icy update in Phase II, the policy design continued to en-
sure the equity of access to GAVI VIG resources among
eligible countries based on the size of the country. How-
ever, with more information available on the costs of new
vaccine introductions ([196], (G. Gandhi, P. Lydon,
E. Furrer, H. Saxenian, A. Nguyen: Costs of Introducing
Childhood Vaccines in Low and Lower Middle Income
Countries: Inputs for GAVI Policy on Introduction Grant
Support to Countries, in press)) as well as the operational
costs associated with GAVI-funded campaigns [197], GAVI
increased funding for routine vaccine introductions from
US $0.30 to US $0.80 per child in the birth cohort with the
minimum still set at US $100,000. GAVI also increased the
funding for operational costs of campaigns that it sup-
ported from US $0.30 to US $0.65 per targeted individual
[198]. While not the driving motivation for the change in
levels of GAVI investments, the increase in GAVI resources
for VIGs and campaign operational costs may have made it
easier in Phase III for national programs to ensure new vac-
cines and campaigns are delivered to a greater proportion of
birth cohorts/target populations, including the harder to
reach. Once again there is as yet no evidence to link the
change in the magnitude of GAVI's investments to changes
in coverage (equitable or otherwise) within eligible countries.
Financial sustainability (Co-financing) policies
Formation/Phase I
Early in Phase I, the GAVI Board articulated a desire for
eligible country governments to achieve “financial sus-
tainability” 29 and to create fiscal space “…such that gov-
ernments can assume the costs of the vaccines and pursue
other immunization delivery goals including improved
equity” (Although the notion of equity here was not fur-
ther elaborated, one can assume that the GAVI Board
intended for governments to use greater fiscal space to
pursue equity improvements within their own countries)
[146, 199]. At the time, GAVI provided vaccines free of
charge to eligible countries with the expectation that by
the end of Phase I, financial sustainability would be
achieved by all countries facilitating the end of GAVI sup-
port. This was based on the assumption that the add-
itional demand generated through GAVI financing would
lead to sufficiently low vaccine prices that would be af-
fordable to developing countries once GAVI support
ended. However, as became apparent by the end of GAVI’s
first phase of operations, the GAVI Board’s expectations
on price declines and the sufficiency of domestic financing
proved to be overly optimistic, particularly given the shift
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towards combination vaccines where vaccine markets
were characterized by less competition at the time [17].
Given this, it seems logical to conclude that the additional
fiscal space expected to enable equity improvements may
not have materialized either although no evidence from
the literature review could be found to support or refute
that supposition. For the purpose of this review, it is as-
sumed that during Phase I, GAVI had neither a clear
framework (despite the above-mentioned objective) nor
any evidence of impact across any dimensions of equity as
related to or facilitated by financial sustainability.
Phase II
Since vaccine prices had not declined to the levels antici-
pated by the end of Phase I, the GAVI Secretariat and Alli-
ance partners discussed how to delay the termination of
GAVI financing, how to help country governments to iden-
tify/create the required fiscal space to finance vaccines, how
to improve access to their immunization programs, and
how to accelerate the vaccine price declines themselves
[108, 200–202]. These broad-ranging discussions laid the
groundwork for GAVI’s co-financing policy, adopted in
2006. The policy required eligible country governments to
take responsibility for a portion of the costs of routine new
vaccines that had been financed by GAVI. GAVI’s co-
financing policy is mentioned here not because there is evi-
dence that it directly impacted inequities in access to
immunization services, but because the architects of the
policy mechanism incorporated (vertical) equity consider-
ations when defining co-financing levels: Eligible countries
were grouped according to their ability to pay using a variety
of proxy criteria.30 These country groupings defined the co-
financing requirements for new vaccines adopted with sup-
port offered during Phase II [203]. The co-financing policy
groupings implicitly affected a more equitable allocation of
GAVI’s resources in Phase II for new vaccine support. Coun-
tries with lower national incomes, and/or greater fragility re-
ceived a greater share of GAVI resources on a per dose
basis, as compared to wealthier and more stable countries.
The literature and recent independent evaluations to date
have been silent on the equity impacts of this policy [27].
Phase III
GAVI also updated its co-financing policy in 2010 with
the new policy taking effect in Phase III. While the Alli-
ance acknowledged the central importance of health finan-
cing more broadly to ensure strong health systems and
immunization programs, the updated co-financing policy
sought to maintain its approach to defining co-financing
levels for GAVI-funded vaccines on an equitable basis.
Under this iteration of the policy, co-financing levels were
based on average national per capita income alone as a
proxy for country’s ability to pay [63, 204, 205]. This main-
tained and refined GAVI’s between-country vertical equity
approach in allocations of GAVI resources for new vaccine
support such that on a per dose basis, lower income coun-
tries (as defined by GNI per capita) paid less, and accord-
ingly receive a greater share of GAVI resources than
wealthier countries. In practice, as noted by a recent evalu-
ation, the policy has not been applied consistently across
vaccines with some vaccines exempted (e.g. HPV demon-
stration projects, JE and Rubella campaigns) [27]. This
may have created implicit financial incentives to prioritize
some vaccine programs over others, and inadvertently al-
beit very marginally, affected between- and within- coun-
try inequities in disease burden. However, no evidence
could be found to substantiate or refute this supposition.
‘Fragile States’ policies
Phase I
GAVI had no specific policies designed to support fragile
states31 nor did any of the policies in GAVI’s first phase
of operations have specific features to address the needs
of such countries. Despite this, the Phase I evaluation in-
terrogated the differences in the likelihood and amount
of GAVI support received among different types of
countries including those classified by the World Bank
as being a LICUS versus non-LICUS country.32 Overall,
the evaluation found that GAVI’s policies and require-
ments for country support resulted in relatively more
funding per infant allocated toward three non-exclusive
groups of countires: LICUS countries, those countries
with lower DTP3 coverage rates at the inception of
GAVI, and those countries with lower average per capita
incomes. However, the evaluators also found evidence
that LICUS countries were not as well able to make
good use of the funding, and worse still found that GAVI
funding had essentially no measurable impact in coun-
tries with an ongoing conflict (i.e. within a subset of
LICUS/fragile states). The evaluators summarized that
the design of GAVI support in Phase I “may not be ap-
propriate for LICUS countries, which tend to have lower
rates of uptake and achieve lower results” [17].
Phase II
Building on the findings from the Phase I evaluation, the
GAVI Phase II Strategy proposed to measure GAVI’s
progress to improve coverage in fragile states and Coun-
tries with Large numbers of Unimmunized Children
(CLUCs) by assessing changes in geographic inequities
in immunization coverage (the proportion of the popula-
tions in these countries that had ‘increased or sustained
DPT3 and measles coverage at national and district
level’) [153]. There was little in the way of GAVI-specific
policies and programs specifically designed to address
geographic inequities in access to immunization services
within countries and especially for the subsets of coun-
tries described as Fragile States or CLUCs beyond (i)
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encouragement to use GAVI cash-based support to
address specific areas or groups of the population; (ii)
funding to WHO and UNICEF for technical assistance
(TA) to assist countries to increase and sustain their
coverage at high level; (iii) funding to WHO and
UNICEF specifically to continue strengthening their own
and national capacity in CLUCs [155]. On all these
fronts, evidence of the outcomes associated with these
efforts is sparse and somewhat inconsistent. What infor-
mation is available suggests that the Alliance as a whole
did not make much progress. With respect to the TA
provided by WHO and UNICEF, a significant part of Al-
liance partner efforts seems to have focused on the def-
inition of corrective actions based on ‘Reach Every
District (RED) strategies’ and their implementation
[206–208]. While GAVI’s Phase II Evaluation doesn’t
comment specifically on the effectiveness of those ef-
forts, separate evaluations of RED strategies in India and
the African region suggest improvements in the quality
of services and/or levels of immunization coverage
[209–211]. These evaluations however say little about
the impacts of RED strategies to address inequities in ac-
cess to immunization. The evaluations struggled to attri-
bute effects observed to the specific RED interventions
and some of the evaluations draw on data that relates to
GAVI’s first- rather than second- phase of operations, and
draw upon work not solely funded by GAVI. Reports by
the GAVI Secretariat documenting annual work plan
achievements for 2007 are somewhat contradictory with
respect to CLUCs. One states that “By 2007, all seven
CLUCs (Nigeria, Pakistan, India, Ethiopia, Sudan, DRC,
Indonesia) had begun to implement Reach Every District
(RED) planning, an approach that aims at improving the
organisation of immunisation services so as to guarantee
sustainable and equitable immunisation for every child.
Five out of the seven CLUCs had improved their routine
DTP3 and measles coverage by 10 % over 2005 levels”
[182]. Another report from around the same time explains
“…substantial changes have taken place in thinking re-
garding support to fragile support to fragile states and
Countries with a Large Number of Unimmunised … While
initially the intent was to provide these countries with add-
itional technical and funding support to overcome their
features through the possible expansion in the funding win-
dows, the current thinking sees these features are ‘modifiers’
to the existing GAVI application and reporting rules as
well as modifiers to funding allocations” [212]. The GAVI’s
Phase II Evaluation points out that the Alliance failed to
formalize criteria to define a list of CLUCs or fragile states.
Hence the Alliance’s added value in this important set of
countries could not be measured [18].
The Alliance did attempt to develop a specific strategy
for fragile states in Phase II agreeing on a definition of
fragility based on the World Bank definition [183, 213].
As the GAVI Board came to consensus on the use of
that third party definition, a World Bank independent
evaluation of the Bank’s own support to LICUS noted
that the Bank would need to reexamine the appropriateness
of the criterion to identify LICUS given the shortcomings
of the indicators and criteria used [214]. This stymied
GAVI’s efforts to develop a fragile states policy in Phase II.
Given that GAVI did not develop and implement a fra-
gile states policy, GAVI was unable to tackle how funding
applications or application reporting requirement should
be altered to address the unique circumstances in fragile
states and CLUCs. As a result, it seems reasonable to
summarize that the Alliance did not find a way to address
the inequities in access to immunization within fragile
states and CLUCs, nor between these countries and other
countries during its second phase of operations.
Phase III
Early in Phase III, the GAVI Board adopted a policy on
fragility and immunization [215]. Noting the many lists
and definitions had been developed to identify and/or
categorize fragile states, and that 77 % of GAVI coun-
tries could be considered as 'fragile' on at least one of
these lists, the Board approved a country-by-country ap-
proach for a subset of countries facing particular chal-
lenges rather than developing a policy centered on a
specific fragile states definition. The objectives of this
tailored approach policy are to protect immunization
systems and existing GAVI support in case of emergency
events, and to improve vaccination coverage in a subset
of countries with particularly "challenging circumstances"
(e.g. not applying for, accessing or utilizing GAVI sup-
port, CLUCs, countries with national DTP3 coverage
levels <70 %, or countries with “equity concerns”) [216].
The policy defines countries with equity concerns as be-
ing those countries with significant subnational, socio-
economic or gender differences in immunization
coverage defined by the following criteria: greater than
50 % of districts reporting DTP3 coverage <50 % (to
measure subnational disparities); where the difference in
DTP3 coverage between the lowest wealth quintile and
the highest wealth quintile is greater than 20 % points
(to measure socioeconomic disparities); and/or where
the odds ratio confidence interval (female versus males)
in sex-disaggregated coverage does not include the value
1 (to measure gender inequalities) [217]. In these sets of
country-specific circumstances, the policy enables GAVI
to make additional resources available to address the situ-
ations, tailor support, re-program cash support, channel
cash-based support and/or vaccines through in-country
Alliance partners (e.g. WHO, UNICEF) or through non-
state actors (e.g. CSOs). The policy also offers flexibilities
in the application of GAVI policies (e.g. co-financing)
[216]. While the policy implementation is in its infancy, it
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offers significant potential with respect to reduction of
within-country inequities in access to immunization ser-
vices in a subset of GAVI countries.
Beyond the country-by-country policy, in Phase III,
GAVI has acknowledged a need to sharpen its approach
to address the needs of fragile states in two additional
ways. Firstly, GAVI has provided modest funding to the
CSO constituency through Catholic Relief Services
(CRS). With this funding, CRS is supposed to facilitate
the development of national networks of CSOs in order
to promote their engagement in the policy dialogue,
service delivery, and more specifically in the design
and implementation of the HSS grants to support
immunization. In theory, all of these measures could
contribute to equity improvements within a country
[218]. Secondly, and related to the above point, GAVI’s
IRC has highlighted the interrelated issues of conflict
and inequities within GAVI countries since populations
affected by conflict are often displaced, not well-served
by government programs, or worse still 'invisible' to the
government-led programs. Accordingly, the IRC has
underscored the need for GAVI to rethink its modest
support and light-touch approach to CSOs (given the
importance of CSOs in addressing the needs of popula-
tions affected by conflict) [100, 102, 103]. While GAVI
has yet to respond to the IRC’s recommendations in this
regard, the IRC does now regularly profile the extent to
which CSOs have been involved in NVS and/or HSS
proposal development and planned program efforts [97,
100–103]. No evidence is currently available to demon-
strate whether these efforts have resulted in positive im-
pacts on inequities within GAVI countries and especially
those characterized by fragile contexts.
Gender policy
Phase I
In GAVI’s first phase of operations, it had no specific
Gender Policy nor any programs focused on addressing
gender disparities. Nonetheless, as aforementioned, the
Phase I evaluation noted that disparities in immunization
coverage based on gender were reduced during Phase I
and changes were correlated to GAVI funding [17].
Phase II
On the basis of an independent report commissioned by
the GAVI Secretariat [219], in 2008, mid-way through
Phase II, the GAVI Board approved GAVI’s first Gender
Policy to address gender inequalities in access to and
coverage of immunization within GAVI countries. The
policy encouraged countries and partner organizations to
support the generation, reporting and analyses of new
gender-related evidence with respect to immunization
(e.g. gender-disaggregated coverage data). The policy also
urged countries to build on such data and to strive for a
gender-sensitive national immunization policy , and to
more broadly encourage gender equality in health [86, 220].
However, the original independent report that provided the
foundations of GAVI’s Gender Policy was poorly received
and the policy was not widely supported across the
Alliance. This lead to further assessments and guidance by
the WHO’s Initiative for Vaccine Research (IVR) and its
Strategic Advisory Group of Experts (SAGE) on gender
equality in immunization [221, 222]. These assessments
suggested that childhood immunization programs aren’t
broadly characterized by gender disparities in coverage.
Given the initial disagreement regarding the evidence that
informed GAVI’s Gender Policy, it is no surprise that
GAVI’s Phase II Evaluation is silent about GAVI’s impact
on gender inequalities during its second phase of opera-
tions [18]. A more recent and specific evaluation of
GAVI’s Gender Policy that assesses the policy’s impact
within Phase II and beyond suggests that the main
achievements of the policy have primarily benefitted GAVI
Secretariat staff and influenced GAVI’s own governance
structure (due to more emphasis on gender equality
within the GAVI Secretariat and on the GAVI Board). The
evaluation noted that significant effects within GAVI
countries - in terms of reductions in gender disparities in
immunization coverage where they exist, and more im-
portantly efforts to address gender-related barriers to ac-
cess - had yet to be fully realized [23].
Phase III
Building on findings from the HSS evaluation [22] as well
as the Gender Policy evaluation [23], GAVI revised its
Gender Policy in 2013. The revised policy shifted and
broadened the programmatic focus of GAVI efforts related
to gender beyond gender-disaggregated immunization
coverage data. The new policy underscored: the import-
ance of analyzing gender-related barriers to access and
utilize vaccination, and strategies to overcome said bar-
riers in NVS and HSS proposals. The policy additionally
emphasized the need for GAVI to integrate gender aspects
in its program guidelines, application materials, and appli-
cation review criteria. Finally, the new policy committed
GAVI to increase accountability for gender-related results
throughout the Alliance, including in the review of pro-
gram performance [223]. The impact of this new policy on
outcomes has yet to be documented. Through the recent
IRC reports, it seems that there has not been much pro-
gress in the extent to which country applications have
identified, or sought to address, gender-related barriers.
The proportion of applications that identify gender-related
barriers was 12 % in 2012, 24 % in November 2013, 13 %
in February 2014, and 9 % in April 2014. The proportion
of applications that propose strategies to address gender-
related barriers identified are lower still [97, 100, 101].
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Program prioritization
Phase III
Following the Global Financial Crisis of 2007–2008, and
with growing demand from eligible countries for GAVI
funding, the Alliance came to realize that unless donors
significantly increased their contributions, and program
efficiencies could be found, GAVI would be unable to
fund new programs from 2012 onwards [224, 225]. A
pilot mechanism to prioritize among country funding
applications was developed for use only in the instance
that resources became insufficient to fund new programs
[226]. One of the six objectives of this mechanism was
to “Distribute GAVI’s resources more equitably among
countries”33. In order to achieve this between-country
equity objective, the mechanism proposed the use of a
simple rule: only one new vaccine proposal per country
should be considered for funding in each proposal round
[226]. It was also noted that other criteria to rank vac-
cine applications – such as health impact and per capita
income – would also address between-country equity di-
mensions by prioritizing country applications with the
greatest ability to avert deaths per 1000 vaccinated and
with the least ability to pay for the vaccines [227]. The
mechanism did not explicitly consider prioritization (or
de-prioritization) of proposals based on levels of within-
country inequities since GAVI neither wanted to reward
countries with large internal inequities in immunization
coverage, nor penalize countries with more fairly distrib-
uted and accessed immunization services. To date, the
prioritization mechanism has not been employed to in-
form funding decisions given the generosity of GAVI's
donors [165]. As a result, the mechanism’s effect on
within- and between- country equity has been neutral.
Discussion
Equity of opportunity: Access to new and underutilized
vaccines
GAVI’s formation and subsequent phases of operations
have been characterized by a drive to address the inequities
in access to vaccines/antigens between higher-income (in-
eligible) countries and lower-income (GAVI-eligible) coun-
tries. Evidence suggests that the Alliance has been most
successful and most consistent across its phases of opera-
tions to date in addressing these particular inequities.
Those successes have been primarily mediated through
GAVI’s Vaccine Priorities, Country Eligibility, long-term
and secure funding that GAVI has committed (NVS
grants), and the Alliance’s Supply and Procurement strat-
egies to harness the lowest vaccine prices.
GAVI’s focus on inequities in access to vaccines can be
traced back to the situation observed at the time of
GAVI’s formation; namely, the long lag between new
and underutilized vaccines being made available to
higher-income countries as opposed to lower-income
countries. Consideration of the actors involved in the
formation of the Alliance provides some deeper insights.
GAVI’s first few years were funded mainly by philan-
thropic institutions (most notably, the Bill & Melinda
Gates Foundation and the Rockefeller Foundation) and a
small number of sovereign donors. ‘Global-level’ stake-
holders from these funders and founding partner multi-
lateral agencies (UNICEF, WHO and the World Bank)
drove strategy and policy discussions [228]. Thus, a
focus on addressing inequities between higher-income
countries and lower-income countries may reflect the
viewpoint of these stakeholders at the time—a view of
the ‘developing world’ from the ‘developed world’. That
said, many of the policy/funding levers to address the
between-country inequities in access to vaccines – most
notably increasing funding availability, and pooling that
funding and procurement to facilitate access to more
affordable vaccine prices – are levers that global stake-
holders in particular have been best positioned to operate.
In trying to address inequities in access to vaccines be-
tween lower-income countries and higher-income coun-
tries, over time GAVI has reduced inequities between
lower income countries themselves. While this was not an
explicit goal of the Alliance during any of its phases, this
has been an important and lasting result.
Equity of opportunity: Access to and/or allocation of
GAVI resources
Throughout each phase of its operations, like most global
funding mechanisms, GAVI has had to optimize resource
allocation decisions within its semi-fixed budget con-
straint. In terms of resource allocation mechanics and
program policies, GAVI focused almost exclusively on
between-country equity concerns. With the exception of
the Country Eligibility policy, this focus dealt with equity
between GAVI countries alone. In most instances, policies
dealing with access to GAVI resources have been driven
by vertical equity concerns: they sought to apportion
greater resourcing to greater needs. However, the mea-
sures of need have often differed from policy to policy. For
Country Eligibility and Co-financing, needs have been pri-
marily been defined in terms of ability to pay for vaccines;
for Cash-Based Support (depending on the specific pro-
gram) needs have generally been determined by country
size, average wealth, and NIP performance; for VIGs,
needs have been based on country size. It is also worth
highlighting two new/revised policies unveiled in Phase
III—the Fragile States policy (Country-by-Country Ap-
proach), and the PBF-focused HSS/Cash-Based Support:
These are the first GAVI policies that explicitly allocate
greater GAVI resources towards greater need but where
need also includes within-country inequity considerations.
One deviation from a vertical equity approach has
been the implementation of Country Budget Caps in
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Phase I and II for a handful of large countries. While coun-
try size was the motivating factor for use of budget caps,
the magnitude of the country-specific caps themselves
appear arbitrary at least as compared to relative need.
Evidence on how GAVI’s two largest (formerly) eligible
countries – India and China – targeted their limited alloca-
tions illustrates the inherent conflict between equity and ef-
ficiency in health resource allocation decisions [229]. GAVI
itself has made similar trade-offs between equity and effi-
ciency through its employment of the DTP3 filters in the
eligibility policies. Recent modeling evidence pertaining to
a cadre of child health interventions including vaccines,
challenges the notion that addressing inequities is not cost-
effective. The research illustrates that when relative disease
burdens are adequately taken into account, targeting the
most deprived areas may actually be as, if not more, cost-
effective than targeting well-performing areas [230].
Perhaps the most controversial of GAVI’s distributive
policies has been the eligibility policy. While a necessity
for any funding mechanism, by applying a principle of ver-
tical equity and continuing to enshrine a country as the
unit of eligibility (as opposed to a country subunit such as
a region or health district), GAVI’s eligibility policies have
naturally created ‘haves’ and ‘have nots’, and has impacted
between-country equity in both positive and seemingly
negative ways. Evidence suggests that for some vaccines/
antigens at certain time-points, many of the countries that
minimally exceed GAVI’s eligibility thresholds have had
slower rates of adoption of new vaccines than many GAVI
countries. This review alone cannot answer the extent to
which this inequity is perpetuated by a lack of access to
GAVI resources and favorable pricing versus other factors
at the government level and beyond GAVI’s control (e.g.
political will to introduce a new vaccine, accompanying
government investment in immunization services). Further
research to assess the nature of inequities between GAVI
and non-GAVI countries has been undertaken – led by
WHO – in the development of a 'Shared MICs Strategy'
to address the immunization needs of MICs.
Finally, since GAVI’s major donors have been a strong
voice in the governance of the Alliance, the scope and de-
sign of GAVI’s strategies, policies, and programs may be
strongly influenced by resourcing considerations. This may
have been particularly important during GAVI’s third phase
of operations when much of the strategy, work plan, pro-
gram and policy re-design coincided with the international
financial crisis. This was a time when many overseas de-
velopment assistance (ODA) budgets among GAVI’s
sovereign donors came under more intense scrutiny
from domestic taxpayers and politicians [231, 232].
That broader backdrop may have colored the strategic
and policy choices taken by the Board at that time
and may have affected the extent to which GAVI
invested in certain pro-equity strategies.
Equity of (intermediate) outcome: Utilization of
immunization services
While GAVI’s overriding goal has been addressing
inequities in access to vaccines, at formation there was a
secondary priority to address inequities between coun-
tries in utilization of immunization services. This was
driven by the fact that many lower income countries at
the time were characterized by stagnating or falling
national immunization coverage. GAVI’s effects on redu-
cing these inequities and raising national coverage rates
in GAVI countries is well understood. Since most ineli-
gible countries have had significantly higher coverage
rates than the majority of eligible countries, observed
improvements among GAVI countries would naturally
reduce these between-country inequities. The evidence
across GAVI’s phases of operations illustrates the most
rapid improvements in coverage in Phase I although
these improvements appeared not to benefit countries
characterized by some form of fragility as much as other
countries. In later phases, evidence on reductions in
immunization coverage/utilization inequities has been
patchier – and immunization coverage data illustrate
that there are still many children who are not fully
immunized. In aggregate, the trends suggest that GAVI’s
efforts to address inequities between countries in
utilization of immunization services have addressed the
‘quick wins’ while the hardest to reach populations often
in the countries with weakest systems and poor govern-
ance have at least until recently, remained underserved.
Addressing within-country inequities in utilization of
immunization services - particularly in GAVI’s first two
phases of operations - was not a central goal for GAVI.
This relative lack of prioritization is likely related to
three factors: (i) vaccines themselves are considered to
be among the most equitable interventions; (ii) at
GAVI’s inception coverage rates in most GAVI countries
were so low that targeting underserved/marginalized/un-
reached communities was not a priority; (iii) data sys-
tems wouldn’t have allowed for such targeting in any
case. This author will discuss each of this points in turn.
Vaccines are generally regarded as highly equitable in-
terventions (e.g. targeting boys and girls alike) and, most
importantly, capable of conferring population-wide herd
immunity benefits against VPDs at high enough levels of
coverage. For much of GAVI’s first two phases of opera-
tions, within-country equity considerations were felt to
be subsumed within efforts to raise national coverage
levels – after all, 100 % national immunization coverage
implies zero inequities within countries. GAVI’s leader-
ship at the time implicitly assumed that provision of
cash-based support (ISS, HSS) to raise national
immunization coverage levels would lead to reductions
in subnational disparities. The majority of GAVI’s targets
and indicators that explicitly consider immunization
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coverage have almost always been based on national
average estimates (rather than subnational measures that
consider pockets of inequity in access to- and utilization
of- immunization services within countries). This reli-
ance on national averages resonates with the approach
pervasive throughout the global development agenda
over the past 10 to 15 years and one that has character-
ized the MDG efforts. It is now recognized that reliance
on national averages alone to measure global develop-
ment progress has been a significant weaknesses of the
‘MDG approach’. Recent evidence illustrates that across
many countries, reliance and focus on national averages
alone has led to an exacerbation of inequities in access
[10–14]. At some point, one has to acknowledge and
focus efforts to reach underserved/marginalized/un-
reached communities explicitly – especially when those
communities are separated from proximity to better
served communities and unlikely to avail from herd im-
munity benefits.
At GAVI’s inception coverage rates in many GAVI
countries were so low34 that reducing the total numbers
of unimmunized children may well have been an accept-
able primary focus rather than prioritizing underserved/
marginalized/unreached communities. However, this
assumption overlooks the fact that those communities
often face the greatest risks of disease and malnutrition
(and as such have the greatest chance of benefiting from
immunization) as compared to other communities.
In the early years of GAVI, data systems to determine
performance of immunization programs nationally - let
alone sub-nationally - were very weak in eligible countries.
With inadequate data, designing programs to target and
ameliorate sub-national inequities in access to- and
utilization of- immunization services may have been too
difficult. However, the fact that systems are weak is a poor
justification to not attempt to help those in greatest need.
Perhaps in response to the points above, more recently,
GAVI has increasingly sought to address within-country
inequities in utilization of immunization services in GAVI
countries. GAVI’s third phase of operations has placed
more emphasis on addressing within-country inequities
within the strategy, business plan, Fragile States policy,
and the inclusion of subnational performance-based as-
pects of GAVI’s revised HSS window. Most importantly,
within Phase III, GAVI has provided clearer guidelines to
countries applying for NVS and HSS grants on how to en-
sure inequities and gender disparities are identified and
addressed. The latter owes much to the critical appraisal
of country applications by GAVI’s IRC and the IRC’s rec-
ommendations on how GAVI should continually improve
its guidelines and policies to better address evolving prior-
ities in immunization programs. Aside from the IRC’s rec-
ommendations, the drivers for the above-mentioned shifts
may reflect the fact that GAVI has been so successful at
reducing between-country inequities in access to vac-
cines/antigens – especially for HepB, Hib, YF vaccines and
to some extent PCV– that GAVI can now bring into focus
what have historically been a secondary or tertiary priority.
Looking beyond GAVI, the discourse surrounding the glo-
bal health and development agendas has moved from a
comparison of ‘developed’ and ‘developing’ (or wealthy
and ‘resource-poor’) countries to a more people-centric
approach that demands all development efforts focus on
individuals, including the marginalized and underserved,
no matter where they reside [6, 8]. Indeed, GAVI’s multi-
lateral and CSO partners, and most notably UNICEF, and
Save the Children, have made reaching unimmunized
populations a mantra in global immunization discussions.
The Alliance may well be responding to those prevailing
development trends and the high-level advocacy from
constituents within its own ranks.
Equity of (final) outcomes: Impact of GAVI priorities and
investments on VPDs
As expected, the evidence for GAVI’s impact on final
outcomes in general - let alone equity dimensions of
these outcomes - is most scant. The majority of GAVI’s
impact on reducing inequities in VPDs between coun-
tries has been mediated by acceleration of rates of intro-
duction of new vaccines combined with the steady
expansion of the portfolio of GAVI-subsidized vaccines.
The expansion of VPD priorities means that GAVI is now
able to address an increasing proportion of the burden
that predominantly affect lower-income countries. Most
of the available evidence characterizing the impacts on
these equity outcomes are theoretical or modeled. How-
ever, the evidence suggests that GAVI investments
should in the longer term enable reductions in inter-
regional, inter-generational and gender-related inequi-
ties in VPD burden.
There are specific examples of the magnitude and
speed of GAVI’s impact on final outcomes through facili-
tation of vaccine introductions within GAVI countries.
Unfortunately, these results are not stratified by geog-
raphy, socioeconomic status, or gender. Thus, there are
no data across GAVI countries to assess GAVI’s impact
to reduce inequities in VPD burden within countries.
Conclusions
This qualitative assessment is based almost exclusively
on published and unpublished documents alone and
relies heavily on grey literature. Steps have been taken to
address reporting bias, and to focus on valid and trust-
worthy sources. To complement this review, future
research efforts should illustrate the evolution and quan-
titative effects of GAVI’s efforts to address between- and
within- country inequities in access to new vaccines,
utilization of immunization services, access to GAVI
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resources, and impact on VPDs.4 There may also be
value in complementing this work with a separate litera-
ture review of other Alliance partner document reposi-
tories (e.g. from GAVI’s donors, other multilateral
partners, CSOs, etc.). Finally, there may be value in con-
ducting an ethnographic review given the multiplicity of
views across the Alliance, and the fact that others have
employed these techniques effectively to chart the evolu-
tion of GAVI’s contribution to health systems strength-
ening [189].
Despite the limitations of this assessment, the findings
potentially have great relevance for a wide array of stake-
holders. By highlighting the strengths and deficiencies of
GAVI’s previous strategies, policies, and programs from
an equity perspective and illustrating the areas where
GAVI has been successful, inconsistent, or unsuccessful
in translating strategic intent into credible and robust
evidence of impact, this research may be useful for those
involved in the future design, implementation and evalu-
ation of GAVI-funded immunization programs.
Within GAVI countries, GAVI’s cash-based investments
are intended to bring benefit beyond immunization pro-
grams by more generally strengthening health programs.
In many GAVI countries immunization programs already
serve as the backbone of health supply chains. At the glo-
bal level, immunization is recognized as one of the best
global health ‘buys’ capable of delivering vast returns for
modest investments, particularly for low- and middle-
income countries [233, 234]. The results described here
may be particularly useful as the Alliance embarks upon
the design of the policies and plans the country programs
that will define its fourth phase of operations, from 2016
through 2020, and perhaps future phases of opera-
tions thereafter. What’s more, the GAVI Alliance is a
highly rated multilateral enterprise [235] embodying
innovation in the global health architecture, with the
GAVI Secretariat an increasingly influential actor seeking
to shape the global health agenda [6]. Given this, there
may be analogous lessons for other global partnerships,
and particularly funding mechanisms that share character-
istics with GAVI. While the governance structures, prior-
ities and/or sectors of focus between GAVI and funding
mechanisms such as the Global Fund (formerly the Global
Fund to Fight AIDS, Tuberculosis, and Malaria) and the
Global Partnership for Education (GPE) are different,
there may be valuable lessons concerning strategy, policy
and program design. All of these mechanisms should
strive towards clarity on the type of equity in focus (be-
tween eligible/ineligible countries, among eligible coun-
tries, within eligible countries) and whether one of the
aims for any stream of funding is to address equity of op-
portunity or outcomes. Furthermore, careful consideration
and articulation is needed by these organizations/partner-
ships on whether underlying resource allocation
mechanisms are built on principles of vertical or horizon-
tal equity. Finally, this assessment points to the import-
ance of designing programs in such a way that the equity
impacts are systematically monitored, evaluated and docu-
mented. Ultimately, multi-stakeholder development funds
like GAVI must ensure that strategic intent to improve
equity is translated into action and demonstrable results.
In its next phase of operations, the Alliance can and
likely will demonstrate that it continues to be a highly
effective multi-partner enterprise, capable of learning and
innovating in a world that has changed much since its in-
ception. By building on its successes, developing more co-
herent and consistent approaches to address inequities in
immunization between and within countries, and through
monitoring and evaluating progress, GAVI will be well-
positioned to bring the benefits of vaccination to previ-
ously unreached and underserved communities, ultimately
contributing towards universal health coverage and sus-
tainable development.
Endnotes
1The term “GAVI countries” is generally employed to
denote both GAVI eligible countries as well as countries
in the process of graduating from GAVI support. The
specific definitions of eligible and graduating countries
are delineated in GAVI’s eligibility policy [135] and
graduation procedures [236].
2In the GAVI Alliance Evaluation Workplan 2015 report
to GAVI’s Evaluation Advisory Committee, the GAVI Sec-
retariat notes that it is currently conducting, or planning to
commence End-of-Support Evaluations in at least two grad-
uated countries, Albania and Bosnia & Herzegovina. The
report mentions an Advance Market Commitment (AMC)
Impact Evaluation and Health Systems Strengthening Grant
Evaluations, both due to commence in 2015 [26].
3One paper on this topic does exist although the dis-
course is at a very high level and since it was published
in 2009, it does not comment on the evaluated impacts
of Phase II and progress during Phase III [237]. Another
piece of work was commissioned by the GAVI Secretariat
for internal purposes, to provide a stock-take of how the
GAVI Alliance defines, measures and seeks to address
equity in Phase III. This working paper is not in the public
domain and does not assess GAVI’s approach to address-
ing inequities has changed over time through its programs
and policies, nor does it set out GAVI’s equity impacts on
opportunity versus outcomes. [Vaccine Implementation
Technical Assistance Consortium (VITAC), “The GAVI
Alliance and equity: immunisation for all,” PATH, Geneva,
2013 Unpublished].
4Separate to this qualitative assessment of literature,
analyses of longitudinal immunization program perform-
ance data have been undertaken to assess more objectively,
the possible impact of GAVI’s approaches on observed
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between- and within- country inequities in immunization.
These analyses are described in a separate forthcoming
paper.
5In this review, the terms inequity and disparity are
used interchangeably. These terms are defined here as
differences that are unnecessary, avoidable, unfair and
unjust across any dimension (e.g. wealth, ethnicity, geog-
raphy, gender) [238, 239]. The term inequality, while re-
lated to inequity, is used in this paper specifically with
reference to gender since unlike socioeconomic, ethno-
graphic or other need-based differences, no amount of
difference according to gender is necessary, fair or just.
6It is acknowledged that in some large and often feder-
ated states, the roll out of new vaccines is phased over
two or more years such that a NIP schedule in one re-
gion of a country may—for a time—be different than in
another part of the country. It is also acknowledged that
in a handful of countries that are characterized by mark-
edly heterogeneous and biodiverse environments, risks
of certain VPDs may be much more concentrated in
some regions than others, and as such, vaccination
schedules may differ slightly from one part of the
country to another. However, these are exceptions ra-
ther than the rule, and as such are not explicitly con-
sidered in this review.
7GAVI Committee papers usually cover the same
topics as are eventually reviewed by the GAVI Board
only in more detail, or in a less complete state. As such,
Committee papers were only included where they pro-
vided important additional information (relevant to the
assessment) than could be found in a Board paper.
8Following GAVI’s formation, three goals were specified:
(1) Increase coverage – boost the number of children
whose lives can be saved with the remarkably effective tool
of vaccination. (2) Shorten the time span between regis-
tration of a vaccine product in the marketplace and its
full-scale use in the developing world. (3) Accelerate
the development and introduction of new vaccines [42].
9Phase I ran from 2000–2005 [17], while the Phase II
strategy covered the period 2007–2010 [58]. The year
2006 was a transition year of sorts, in which the new
Phase II strategy was developed.
10Two operating principles in GAVI’s Phase III strategy
that describe GAVI’s principles vis-à-vis addressing
inequities: “Focusing on innovation, efficiency, equity,
performance and results”; and “Ensuring gender equity
in all areas of engagement” [61, 144].
11GAVI’s target in Phase III with respect to equity im-
provement is as follows: To improve equity in immun-
isation coverage from baseline levels as measured by the
performance indicator—the percentage of GAVI coun-
tries where the DTP3 coverage in the lowest wealth
quintile is ±20 percentage points of the coverage in
highest wealth quintile [240].
12The strategic objective in GAVI’s Phase III strategy
that articulates GAVI’s aims with respect to equity is as
follows: “Increase equity in access to services” [61, 144].
13In Phase III, GAVI renamed the Workplan as ‘the Busi-
ness Plan’ – The name change signified a more rigorous
approach that attempted to link back TA activities through
a coherent logical framework to the overarching strategy.
14Four of the countries identified as having large
disparities in immunization coverage overlapped with
countries characterized by low coverage (i.e. DTP3 < 70 %
nationally). In these countries, WHO and UNICEF have
co-led TA efforts to simultaneously improve both overall
national coverage rates and geographic inequities in
subnational coverage.
15In order to evaluate vaccine portfolios, the VIS IRC
used the following seven priorities: i). Prioritise potential
integration with EPI schedule (<12 months); ii). Prioritise
potential integration with an extended EPI schedule
(<18 months); iii). Focus on highly effective vaccines
(>75 % effectiveness in GAVI countries); iv). Focus on
diseases for which no adequate treatment is currently avail-
able; v). Focus on diseases for which no adequate preven-
tion is currently available; vi). Prioritise vaccines that
address inequity of the poor (relating to diseases dispropor-
tionally affecting the poor, or to vaccines specifically benefi-
cial to the poor); vii). Prioritise vaccines that address gender
inequity (relating to diseases disproportionally affecting one
sex, or to vaccines specifically beneficial to one sex).
16While GAVI-funded MenA vaccine campaigns com-
menced in a handful of countries at the end of phase II
(along with support for the MenA vaccine stockpile)
following the approval of a MenA vaccine investment
case [86, 87], the majority of these vaccines were
planned for roll out in phase III as and when appropriate
conjugated vaccines became available.
17While it is not well-known, at the time of GAVI’s
first three Board meetings, the list of eligible countries
was initially proposed (in the Board materials) as being
defined based on those countries with an annual GNP/
per capita equal to or less than US $1,000 and a total
national population of less than 150 million people [49,
107]. This ruled out three large countries: China, India
and Indonesia. However, the strict population criterion
was removed, and replaced with a different approach to
large countries as discussed in the section entitled 'Large
countries and budget cap policies' of this paper.
18In 1999, at the time of the first Board meeting, there
were initially 71 eligible countries [68 countries with per
capita GNP ≤US $1,000 and a population less than 150
million, three countries with uncertain per capita GNP
but anticipated to be below or close to $1,000 (Cuba,
Democratic Peoples’ Republic of Korea, and Ukraine)].
In addition, there were three further more countries
with per capita GNP ≤US $1,000 and a population above
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150 million (China, India and Indonesia) whom, as
noted in the footnote above and in the section of this
paper entitled 'Large countries and budget cap policies'
would be considered partially eligible through the re-
mainder of phase I [116]. In 2002, following the coun-
try’s formation (and recognition by the United Nations),
Timor-Leste was added to the list of eligible countries
taking the total number of GAVI countries to 75
through the remainder of Phase I.
19In 2003, the World Bank adopted the 1993 System
of National Accounts (SNA) and as such changed its
terminology from GNP per capita to Gross National
Income (GNI) per capita. This alteration however, did
not have an impact on the country statistics them-
selves or the ranking that informed GAVI’s country
eligibility [241].
20An update of the eligibility criteria reference data
was considered midway through Phase I, but it was
decided to hold the eligibility policy constant to ensure
predictability [242, 243].
21At the time, this funding was referred to as the New
and Under-used Vaccines sub-account from the Global
Fund for Children’s Vaccines (The Fund).
22At the time, this funding was referred to as the
Immunization Services sub-account of The Fund.
23At the time of the update, 26 GAVI-eligible coun-
tries, representing 55 % of GAVI’s birth cohort, were
above the US $1,000 GNI per capita threshold according
to the latest GNI data (published by the World Bank for
the financial year 2008). In addition, there were 23 coun-
tries not eligible for GAVI support whose incomes were
below that of the wealthiest eligible GAVI country [145].
24It is recognized that the terms “poor countries” and
“poor people” are pejorative and no longer commonly
used. However, they are used here only because it the
parlance used in GAVI policy documents, Committee
and Board papers during the time.
25In June 2010, following slow progress to develop and
implement a mechanism to improve coverage in
countries with low coverage, the GAVI Board decided
to temporarily suspend the November 2009 decision
of the Board to raise the DTP3 filter to 70 % thereby re-
establishing the filter threshold at 50 % for 2010 round of
new vaccine support applications – and until GAVI’s
new performance-based funding had been designed
and launched.
26The GOI also selected high-performing districts as it
was felt these would be better placed to monitor and
manage AEFIs and vaccine wastage.
27The HSS evaluation provides the following additional
information: “The approach to equity is mixed. In some
countries certain districts or provinces have been targeted
based on a range of criteria, including current immunisa-
tion performance, availability of infrastructure/transport/
human resources as well as socio-economic indicators:
Vietnam, Bhutan, Burundi, DRC, Honduras (focused on
104 municipalities), Nicaragua (which focused on specific
municipalities), Zambia (12 districts), Yemen (64 districts),
Cambodia (10 ODs), Nepal (varies by component), Sri
Lanka and Ghana all fall into such category. However,
there is often little focus on ensuring that those most in
need within those geographical areas are targeted. This is
an important distinction in countries where, for instance,
socio-economic status plays a higher role in accessing
health care than geographical location. In other countries
a national approach is adopted in some cases more be-
cause all areas are seen as equally poor (Liberia, Sierra
Leone) or others where it was seen as the best way to move
forward (as in Rwanda, where new districts might not have
had at the time of design sufficient planning experience to
enable a more differentiated district approach)” [22].
28The ten countries are Afghanistan, Bolivia, Democratic
Republic of Congo, Ethiopia, Indonesia, Mozambique,
Pakistan, Ghana, Burundi, and Georgia (although Bolivia,
Georgia and Mozambique had not received CSO funding
support by the time of the independent evaluation.
29Specifically, in June 2001 the GAVI Board adopted
the following definition of financial sustainability: “Al-
though self-sufficiency is the ultimate goal, in the nearer
term sustainable financing is the ability of a country to
mobilize and efficiently use domestic and supplementary
external resources on a reliable basis to achieve current
and future target levels of immunization performance in
terms of access, utilization, quality, safety and equity”.
(Emphasis added) [146].
30GAVI’s original co-financing policy country groupings
used the following criteria: GNI per capita (i.e. countries
with a GNI p.c. ≤ US $1,000 versus countries with a GNI
p.c. >US $1,000), UN development status (i.e. least devel-
oped countries (LDCs) versus non-LDCs), and fragility
(i.e. defined by the World Bank as a ‘Fragile State’) [203].
31It is recognized that the term “fragile states” is
considered pejorative and no longer commonly used. It
is used here only because it reflected the parlance used
in GAVI policy and strategy documents and Board pa-
pers, particularly during Phase II.
32The Bank uses two criteria to classify countries as
LICUS: (i) low-income; and (ii) poor performance on
Country Policy and Institutional Assessment (CPIA).
Lists of the countries classified by the World Bank as
LICUS for the financial years 2006–2009 can be found
online [244].
33Other objectives of GAVI’s pilot prioritization
mechanism are as follows: Maximize overall health
impact (i.e. reduction of disease burden); Maximize
value for money (i.e. cost-effectiveness); Reinforce the
financial sustainability of immunization programs;
Focus GAVI’s support on countries with the greatest
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need/least ability to pay; Ensure country readiness for
use of GAVI-supported vaccines [226].
34Roughly one third of GAVI countries had DTP3
coverage below 50 %, and roughly one sixth of GAVI
countries had coverage below 40 % in 1999.
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